var title_f5_52_5952="Inflatable penile implant";
var content_f5_52_5952=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F54550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F54550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inflatable penile implant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 231px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With an inflatable implant, erection is produced by squeezing a small pump (a) implanted in the scrotum. The pump causes fluid to flow from a reservoir (b) residing in the lower pelvis to two cylinders (c) residing in the penis. The cylinders expand to create the erection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_52_5952=[""].join("\n");
var outline_f5_52_5952=null;
var title_f5_52_5953="Mobilization of left colon from lateral peritoneal attachments";
var content_f5_52_5953=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F69062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F69062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Mobilization of left colon from lateral peritoneal attachments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 626px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_52_5953=[""].join("\n");
var outline_f5_52_5953=null;
var title_f5_52_5954="Glomus tumor surgery";
var content_f5_52_5954=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F85741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F85741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Surgical excision of glomus tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 434px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_52_5954=[""].join("\n");
var outline_f5_52_5954=null;
var title_f5_52_5955="Docusate and senna: Pediatric drug information";
var content_f5_52_5955=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Docusate and senna: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8115?source=see_link\">",
"    see \"Docusate and senna: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/0/31747?source=see_link\">",
"    see \"Docusate and senna: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Doc-Q-Lax [OTC];",
"     </li>",
"     <li>",
"      Dok&trade; Plus [OTC];",
"     </li>",
"     <li>",
"      Geri-Stool [OTC];",
"     </li>",
"     <li>",
"      Peri-Colace&reg;  [OTC];",
"     </li>",
"     <li>",
"      Senexon&reg;-S [OTC];",
"     </li>",
"     <li>",
"      Senna Plus [OTC];",
"     </li>",
"     <li>",
"      SennaLax-S [OTC];",
"     </li>",
"     <li>",
"      Senokot-S&reg; [OTC];",
"     </li>",
"     <li>",
"      SenoSol&trade;-SS [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Laxative, Stimulant",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Laxative, Surfactant",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Stool Softener",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8115?source=see_link\">",
"      see \"Docusate and senna: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 2 to &lt;6 years:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     tablet once daily at bedtime; maximum: 1 tablet twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6 to &lt;12 years: 1 tablet once daily at bedtime; maximum: 2 tablets twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years, Adolescents, and Adults: 2 tablets once daily at bedtime; maximum: 4 tablets twice daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F220500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: Docusate sodium 50 mg and sennosides 8.6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Doc-Q-Lax: Docusate sodium 50 mg and sennosides 8.6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dok&trade; Plus: Docusate sodium 50 mg and sennosides 8.6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Geri-Stool: Docusate sodium 50 mg and sennosides 8.6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peri-Colace&reg;: Docusate sodium 50 mg and sennosides 8.6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Senexon&reg;-S:  Docusate sodium 50 mg and sennosides 8.6 mg [contains calcium 20 mg/tablet, sodium 6 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SennaLax-S:  Docusate sodium 50 mg and sennosides 8.6 mg [contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Senna Plus: Docusate sodium 50 mg and sennosides 8.6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Senokot-S&reg;: Docusate sodium 50 mg and sennosides 8.6 mg [sugar free; contains sodium 4 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SenoSol&trade;-SS: Docusate sodium 50 mg and sennosides 8.6 mg [contains sodium 3 mg/tablet]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F220492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with water, preferably in the evening",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of constipation generally associated with dry, hard stools and decreased intestinal motility; prevention of opiate-induced constipation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F220527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Senokot&reg; may be confused with Depakote&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F220526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urine discoloration (red/brown)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to docusate, senna, or any component; concomitant use of mineral oil; undiagnosed abdominal pain; appendicitis, intestinal obstruction or perforation; acute abdominal pain; nausea, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid prolonged use (&gt;1 week); chronic use may lead to dependency, fluid and electrolyte imbalance, vitamin and mineral deficiencies",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use when abdominal pain, rectal bleeding, nausea, or vomiting are present",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I &amp; O, frequency of bowel movements, serum electrolytes if severe diarrhea develops",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Senna's active metabolite (aglycone) acts as a local irritant on the colon and stimulates the myenteric plexus to produce peristalsis; docusate reduces surface tension of the oil-water interface of the stool resulting in enhanced incorporation of water and fat allowing for stool softening",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1049885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Within 6-12 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Senna:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Senna is metabolized in the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In the feces (via bile) and in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1049878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/0/31747?source=see_link\">",
"      see \"Docusate and senna: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May discolor urine or feces; drink plenty of fluids",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Baker SS, Liptak GS, Colletti RB, et al, &ldquo;Constipation in Infants and Children: Evaluation and Treatment. A Medical Position Statement of the North American Society for Pediatric Gastroenterology and Nutrition,&rdquo;",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 1999, 29(5):612-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/52/5955/abstract-text/10554136/pubmed\" id=\"10554136\" target=\"_blank\">",
"        10554136",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Herndon CM, Jackson KC II, and Hallin PA, &ldquo;Management of Opioid-Induced Gastrointestinal Effects in Patients Receiving Palliative Care,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2002, 22(2):240-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/52/5955/abstract-text/11837561/pubmed\" id=\"11837561\" target=\"_blank\">",
"        11837561",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12900 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-ACA0B7D5D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_52_5955=[""].join("\n");
var outline_f5_52_5955=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220510\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049880\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049874\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220500\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220492\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049883\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049882\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220527\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220526\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049887\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049873\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049872\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287238\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049879\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049871\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049885\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049886\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049878\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12900\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12900|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8115?source=related_link\">",
"      Docusate and senna: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/0/31747?source=related_link\">",
"      Docusate and senna: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_52_5956="Cytomegalovirus immune globulin: Patient drug information";
var content_f5_52_5956=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cytomegalovirus immune globulin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24901?source=see_link\">",
"     see \"Cytomegalovirus immune globulin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/16/16645?source=see_link\">",
"     see \"Cytomegalovirus immune globulin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F156155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      CytoGam&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4663230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CytoGam&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691443",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop cytomegalovirus (CMV) disease after organ transplant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cytomegalovirus immune globulin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703771",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have IgA deficiency.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have fluid loss, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a stroke, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11714 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-2A6F391156-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_52_5956=[""].join("\n");
var outline_f5_52_5956=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156155\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4663230\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015177\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015176\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015181\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015182\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015184\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015179\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015186\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24901?source=related_link\">",
"      Cytomegalovirus immune globulin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/16/16645?source=related_link\">",
"      Cytomegalovirus immune globulin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_52_5957="Proximal tibial fractures in adults";
var content_f5_52_5957=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Proximal tibial fractures in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/52/5957/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/52/5957/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/52/5957/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/52/5957/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/52/5957/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/52/5957/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/52/5957/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Closed tibial fractures are common long-bone fractures. Greater than 70,000 hospitalizations, 800,000 office visits and 500,000 hospital days, have been attributed to tibial shaft fractures alone. While the elderly suffer many of these fractures from falls, the presence of significant osteoporosis increases the risk for compound or more complex fractures with higher morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5957/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review issues related to proximal tibial fractures. A general overview of tibial fractures is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26358?source=see_link\">",
"     \"Overview of tibial fractures in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PERTINENT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tibia is the major weight-bearing bone of the lower leg (",
"    <a class=\"graphic graphic_picture graphicRef54800 \" href=\"UTD.htm?41/14/42213\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65590 \" href=\"UTD.htm?26/45/27349\">",
"     picture 2",
"    </a>",
"    ). The proximal portion of the bone, the tibial plateau, forms the lower surface of the knee joint (",
"    <a class=\"graphic graphic_figure graphicRef69611 \" href=\"UTD.htm?34/27/35251\">",
"     figure 1",
"    </a>",
"    ). The thicker of the two articular surfaces is the medial tibial condyle, while the lateral tibial condyle is a relatively thinner and weaker portion of the joint.",
"   </p>",
"   <p>",
"    Separating the medial from the lateral tibial condyle is the intercondylar eminence, an important bony prominence that anchors the attachment of the anterior cruciate ligament (ACL).",
"   </p>",
"   <p>",
"    Another key bony landmark is the tibial tuberosity which is on the anterior surface, several centimeters below the joint line and the inferior patellar pole, which serves as the attachment site for the patellar tendon [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5957/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A strong fibrous structure, the interosseous membrane, connects the tibia and fibula along the length of the two bones. Proximally, this structure, reinforced by strong anterior and posterior ligaments, forms a synovial joint, the proximal tibiofibular articulation.",
"   </p>",
"   <p>",
"    Another fibrous structure, the crural fascia, surrounds the bones and muscles of the lower leg. Fascial extensions and the interosseous membrane separate the muscles, nerves and vessels of the lower leg into four distinct compartments (",
"    <a class=\"graphic graphic_figure graphicRef66579 \" href=\"UTD.htm?4/40/4740\">",
"     figure 2",
"    </a>",
"    ). Three of these, the anterior, posterior and deep posterior compartments all border the tibia and can be compromised by tibial injury.",
"   </p>",
"   <p>",
"    Nerves and vessels lie within the anterior and the deep posterior compartments and trauma that causes significant swelling in these compartments can result in neurovascular compromise. The key blood supply of the tibia arises from periosteal vessels and the nutrient artery. The nutrient artery originates from the posterior tibial artery and enters the posterolateral cortex at the middle third of the tibial shaft near the origin of the soleus muscle. Fractures in this region potentially compromise this blood supply.",
"   </p>",
"   <p>",
"    The periosteal vessels provide a less vulnerable circulation as they derive an abundant blood supply from the anterior tibial artery which travels down along the interosseous membrane. Vascular compromise can arise more proximally from marked effusion of the knee joint or trauma that affects the popliteal artery before it branches into the anterior and posterior tibial arteries or at the level of the anterior tibial artery as it branches off the popliteal artery and passes through a gap in the interosseous membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5957/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tibial nerve and several branches provide the key innervation to the muscles of the lower leg and foot. Nerve roots arise from L4 through S3. The posterior tibial nerve parallels the course of the posterior tibial artery and courses through the deep posterior compartment. In the popliteal space branches of the tibial nerve provide innervation to the posterior compartment and to the popliteus muscle. The deep peroneal nerve branches and follows the course of the anterior tibial artery providing innervation to muscles in the anterior lower leg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant direct trauma, knee hyperextension injuries, and twisting motions in elderly, osteoporotic individuals are among the most common ways that proximal tibial fractures occur. In adults, vehicle-pedestrian collisions, motor vehicle crashes in which the knee is jammed against the dashboard, and hyperextension in contact sports are specific scenarios that lead to injuries to this region [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5957/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYMPTOMS AND EXAMINATION FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury to the proximal tibia may present as a knee effusion or as localized swelling and tenderness over the bone. Pain may limit the examination and obscure important findings. Careful skin inspection is performed to look for",
"    <span class=\"nowrap\">",
"     puncture/missile",
"    </span>",
"    wounds, lacerations, and other evidence of an open fracture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Knee effusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A knee effusion in a patient with a proximal tibial fracture suggests an osteochondral fracture or an internal derangement (eg, meniscal or ligamentous damage). Aspiration often reveals hemarthrosis and the presence of lipid droplets or cellular bone marrow elements is indicative of an intraarticular fracture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5800?source=see_link\">",
"     \"Hemarthrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ligamentous and meniscal integrity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ligamentous and meniscal injuries frequently occur in conjunction with proximal tibial fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5957/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Pain may interfere with accurate assessment of ligamentous and meniscal integrity. Instillation of local anesthetic into the knee joint may facilitate evaluation of these structures, including the anterior drawer",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Lachman test of the ACL, the McMurray test for meniscal damage, and varus and valgus stress testing to evaluate the lateral and medial collateral ligaments, respectively. A detailed description of the use of these and other tests in the evaluation of a patient with knee pain is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=see_link&amp;anchor=H30#H30\">",
"     \"Evaluation of the active adult patient with knee pain\", section on 'Examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More than 10 degrees of opening during varus or valgus stress testing is abnormal. Laxity at the joint line suggests a tear of one of the collateral ligaments, while laxity inferior to the joint line suggests a displaced fracture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Acute compartment syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute compartment syndrome refers to a constellation of symptoms and findings that result from compromised perfusion of one or more of the muscular compartments of the lower leg. Blood or edema within an encircling fascia impairs circulation and results in unrelenting pain, muscle weakness, and hypesthesia or anesthesia in the skin supplied by nerves that course through the fascially enclosed compartment. Of the four compartments of the lower leg, the anterior, superficial posterior, and deep posterior compartments all border the tibia and can be compromised by tibial injury.",
"   </p>",
"   <p>",
"    Tense swelling of the affected muscles, decreased distal pulses, muscle weakness, increased pain elicited by passive stretch of involved muscles, and impaired sensation due to nerve compression or ischemia may be noted on examination. This may progress to pulselessness, paralysis, and anesthesia. Permanent neuromuscular damage may ensue if the compartment pressure is not decreased promptly by fasciotomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard radiographs for suspected proximal tibial fracture include anterior-posterior (AP), lateral, and intercondylar notch views. When clinical suspicion of fracture is high but plain radiographs are equivocal, computed tomography (CT scan) better defines the fracture. Magnetic resonance imaging (MRI) may demonstrate bone bruising and associated meniscus or ligamentous injury [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5957/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. For this reason many clinicians prefer to follow standard radiographs with MRI to define the extent of injury when initial imaging is unremarkable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FRACTURE LOCATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximal tibial fractures are classified for management purposes into those that affect the medial or lateral tibial plateau and fractures of the intercondylar notch.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Tibial plateau fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tibial plateau fractures most commonly involve the lateral plateau after a direct blow that produces a strong force to the lateral knee. Radiographs include lateral, anterior-posterior (AP - (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70950 \" href=\"UTD.htm?40/45/41694\">",
"     image 1",
"    </a>",
"    )), and oblique views (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77716 \" href=\"UTD.htm?28/35/29247\">",
"     image 2",
"    </a>",
"    ) and typically reveal a depression of the lateral tibial plateau in moderate to severe fractures. In more subtle injuries, radiographs may appear normal or show only a slight increase in the density of the bone on an AP view.",
"   </p>",
"   <p>",
"    When clinical suspicion of fracture is high and plain radiographs are equivocal, many clinicians prefer to proceed to MRI because of the ability to visualize bone bruising and associated meniscal or ligamentous injury. CT scanning is another alternative if MRI is contraindicated or not available. CT will better define a fracture but does not allow meniscal or ligamentous injuries to be assessed.",
"   </p>",
"   <p>",
"    Medial tibial plateau fractures require a higher force since this side of the joint has more strength. A strong medial force or an axial load such as landing on one's feet after falling from a height are potential mechanisms. When standard radiographs suggest a medial injury, additional imaging may demonstrate simultaneous fractures of both plateaus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Indications for orthopedic referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures with significant displacement, depression, or those with suspected or documented meniscal or ligamentous damage merit orthopedic consultation within 48 hours. Emergent referral is necessary for fractures that cause vascular injury or compartment syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compression, icing, knee splinting in full extension, elevation, and strict non-weight bearing are the initial phase of treatment of a tibial plateau fracture. At the first follow-up visit the patient is placed in a hinged brace that is locked in full extension and advised to continue non-weight bearing crutch walking, icing, and intermittent elevation of the leg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Follow-up care",
"    </span>",
"    &nbsp;&mdash;&nbsp;After brace fitting, the patient returns weekly for the first three weeks. If there is no displacement at two weeks, the patient begins working on knee flexion in the brace with a goal of 90 degrees by four weeks. Plain radiographs are repeated weekly for three weeks and then on a two to three week basis depending on radiographic appearance.",
"   </p>",
"   <p>",
"    Strict non-weight bearing is the norm for six weeks with adjustment by clinical progress. Partial weight bearing in the brace can begin once there is adequate radiographic healing.",
"   </p>",
"   <p>",
"    Bracing continues until radiographic healing appears complete &ndash; this typically requires 8 to 12 weeks. Quadriceps strengthening follows brace removal. Patients rarely regain full function in less than 12 weeks and more often require 16 to 20 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Return to sport or work",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the individual has regained approximately 80 to 90 percent of the strength of the uninvolved extremity, less stressful job or sport specific functional rehabilitation can begin. This particularly applies to non-weight bearing activities. For more stressful activity or prolonged weight bearing, healing should be nearly complete.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Anterior tibial spine and intercondylar notch fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avulsion of the anterior tibial spine is particularly common in skeletally immature adolescents. In contrast, adults with the same mechanism of injury more commonly have anterior cruciate ligament (ACL) tears. With avulsion, the affected knee often has a significant effusion and aspiration may show blood and or fat indicative of an intraarticular fracture. The treatment of avulsion of the anterior tibial spine is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42807?source=see_link&amp;anchor=H16#H16\">",
"     \"Proximal tibial fractures in children\", section on 'Tibial spine avulsion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Tibial tubercle avulsions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tubercle avulsions occur at the apophysis of the anterior tibia where the patellar tendon attaches. Plain radiographs demonstrate displacement of a reasonable sized fragment. In adolescents, an unfused growth plate may cause confusion with an avulsion fracture. The treatment of avulsion of the anterior tibial tubercle is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42807?source=see_link&amp;anchor=H17#H17\">",
"     \"Proximal tibial fractures in children\", section on 'Tibial tubercle avulsion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/33/12819?source=see_link\">",
"       \"Patient information: Shinbone fracture (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proximal tibial fractures usually result from a fall, motor vehicle crash, vehicle pedestrian collision, or an injury during participation in a contact sport. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Concomitant injury to the stabilizing ligaments",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the medial or lateral meniscus often occurs with proximal tibial fractures. These additional injuries should be suspected, assessed by physical examination, and further evaluated by MRI when clinically indicated. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Symptoms and examination findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Displaced fractures, depressed tibial plateau fractures, intraarticular fractures, associated ligamentous tears,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      meniscal damage warrant orthopedic referral within 48 hours. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Indications for orthopedic referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fractures with vascular injury or suspected compartment syndrome require emergent orthopedic referral. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Acute compartment syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Splinting for tibial plateau fractures is in full extension, while splinting for intercondylar fractures is in 5 to 10 degrees of flexion. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Initial treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Anterior tibial spine and intercondylar notch fractures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial management includes splinting, analgesia, and non-weight bearing with crutches.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5957/abstract/1\">",
"      Schmidt AH, Finkemeier CG, Tornetta P 3rd. Treatment of closed tibial fractures. Instr Course Lect 2003; 52:607.",
"     </a>",
"    </li>",
"    <li>",
"     Duke Orthopaedics. Wheeless' Textbook of Orthopedics. www.wheelessonline.com (Accessed 3/7/05).",
"    </li>",
"    <li>",
"     Patellar, Tibial, and Fibular Fractures. In: Fracture Management for Primary Care, Eiff MP, Hatch RL, Calmbach WL.  (Eds), Saunders, Philadelphia 2003. p.263.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5957/abstract/4\">",
"      Mustonen AO, Koivikko MP, Lindahl J, Koskinen SK. MRI of acute meniscal injury associated with tibial plateau fractures: prevalence, type, and location. AJR Am J Roentgenol 2008; 191:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5957/abstract/5\">",
"      Colletti P, Greenberg H, Terk MR. MR findings in patients with acute tibial plateau fractures. Comput Med Imaging Graph 1996; 20:389.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 205 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-9843F0D5B8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_52_5957=[""].join("\n");
var outline_f5_52_5957=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PERTINENT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYMPTOMS AND EXAMINATION FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Knee effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ligamentous and meniscal integrity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Acute compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FRACTURE LOCATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Tibial plateau fractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Indications for orthopedic referral",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Initial treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Follow-up care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Return to sport or work",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Anterior tibial spine and intercondylar notch fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Tibial tubercle avulsions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/205\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/205|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/45/41694\" title=\"diagnostic image 1\">",
"      Lateral tibial plateau fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/35/29247\" title=\"diagnostic image 2\">",
"      Oblique view tibial plateau fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/205|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/27/35251\" title=\"figure 1\">",
"      Anterior anatomy of knee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/40/4740\" title=\"figure 2\">",
"      Cross section lower leg",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/205|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/14/42213\" title=\"picture 1\">",
"      Anterior anatomy of tibia and fibula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/45/27349\" title=\"picture 2\">",
"      Lateral anatomy of tibia and fibula",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=related_link\">",
"      Evaluation of the active adult patient with knee pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5800?source=related_link\">",
"      Hemarthrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26358?source=related_link\">",
"      Overview of tibial fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/33/12819?source=related_link\">",
"      Patient information: Shinbone fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42807?source=related_link\">",
"      Proximal tibial fractures in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_52_5958="Follitropin beta (recombinant human follicle stimulating hormone): Drug information";
var content_f5_52_5958=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Follitropin beta (recombinant human follicle stimulating hormone): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/28/30148?source=see_link\">",
"    see \"Follitropin beta (recombinant human follicle stimulating hormone): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3882687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Follistim&reg; AQ;",
"     </li>",
"     <li>",
"      Follistim&reg; AQ Cartridge",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F3888770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Puregon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3882690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Gonadotropin;",
"     </li>",
"     <li>",
"      Ovulation Stimulator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3882734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose should be individualized. Use the lowest dose consistent with the expectation of good results. Over the course of treatment, doses may vary depending on individual patient response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Ovulation induction:",
"     </b>",
"     Females:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Follistim&reg; AQ:",
"     </i>",
"     I.M., SubQ: Stepwise approach: Initiate therapy with 75 units/day for at least the first 7 days. Increase by 25 or 50 units at weekly intervals until follicular growth or serum estradiol levels indicate an adequate response. The maximum (individualized) daily dose that has been safely used for ovulation induction in patients during clinical trials is 300 units. If response to follitropin is appropriate, hCG is given 1 day following the last dose. Withhold hCG if the ovaries are abnormally enlarged, or if abdominal pain occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Follistim&reg; AQ Cartridge:",
"     </i>",
"     SubQ: Stepwise approach: Initiate therapy with 50 units/day for at least the first 7 days. Increase by 25 or 50 units at weekly intervals until follicular growth or serum estradiol levels indicate an adequate response. The maximum (individualized) daily dose that has been safely used for ovulation induction in patients during clinical trials is 250 units. If response to follitropin is appropriate, hCG is given 1 day following the last dose. Withhold hCG if the ovaries are abnormally enlarged, or if abdominal pain occurs. See",
"     <b>",
"      \"Note\"",
"     </b>",
"     for dosage adjustment for this product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ART:",
"     </b>",
"     Females:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Follistim&reg; AQ:",
"     </i>",
"     I.M., SubQ: Stepwise approach: A starting dose of 150-225 units is recommended for at least the first 4 days of treatment. The dose may be adjusted for the individual patient based upon their ovarian response. The maximum daily dose used in clinical studies is 600 units. When a sufficient number of follicles of adequate size are present, the final maturation of the follicles is induced by administering hCG. Oocyte retrieval is performed 34-36 hours later. Withhold hCG in cases where the ovaries are abnormally enlarged on the last day of follitropin beta therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Follistim&reg; AQ Cartridge:",
"     </i>",
"     SubQ: Stepwise approach: A starting dose of 200 units is recommended for at least the first 7 days of treatment. The dose may be adjusted for the individual patient based upon their ovarian response. The maximum daily dose used in clinical studies is 500 units. When a sufficient number of follicles of adequate size are present, the final maturation of the follicles is induced by administering hCG. Oocyte retrieval is performed 34-36 hours later. Withhold hCG in cases where the ovaries are abnormally enlarged on the last day of follitropin beta therapy. See",
"     <b>",
"      \"Note\"",
"     </b>",
"     for dosage adjustment for this product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Spermatogenesis induction:",
"     </b>",
"     Males:",
"     <i>",
"      Follistim&reg; AQ, Follistim&reg; AQ Cartridge:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Pretreatment with hCG monotherapy is required prior to concomitant therapy with follitropin beta and hCG. Follitropin beta therapy may be initiated after normal serum testosterone levels have been reached. SubQ: 450 units/week (administered as 225 units twice weekly or 150 units 3 times/weekly). A lower dose of Follistim&reg; AQ Cartridge may be considered. See",
"     <b>",
"      \"Note\"",
"     </b>",
"     for dosage adjustment for this product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose adjustment for Follistim&reg; AQ Cartridge: When administered using the Follistim Pen&reg;, the Follistim&reg; AQ Cartridge delivers 18% more follitropin beta when compared to dissolved lyophilized follitropin beta administered by a conventional syringe. If the above starting doses were previously used when administering a recombinant lyophilized gonadotropin product via a conventional syringe, lower starting and maintenance doses should be considered when switching to Follistim&reg; AQ Cartridge. The following dose conversion may be used:",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Follistim&reg; AQ Dosing Conversion",
"      <sup>",
"       1",
"      </sup>",
"     </caption>",
"     <col align=\"center\" width=\"200\">",
"     </col>",
"     <col align=\"center\" width=\"200\">",
"     </col>",
"     <thead valign=\"bottom\">",
"      <tr>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Dose Administered Using Powder for Solution/Conventional Syringe",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Follistim&reg; AQ Dose Administered Using Follistim Pen&reg;",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot>",
"      <tr>",
"       <td align=\"left\" colspan=\"2\" valign=\"top\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Values listed are rounded to the nearest 25 unit increment.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         75 units",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         50 units",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         150 units",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         125 units",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         225 units",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         175 units",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         300 units",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         250 units",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         375 units",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         300 units",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         450 units",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         375 units",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15896269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15896270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F242595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [rDNA origin]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Follistim&reg; AQ: 75 units/0.5 mL (0.5 mL); 150 units/0.5 mL (0.5 mL) [contains neomycin (may have trace amounts), streptomycin (may have trace amounts), sucrose 50 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Follistim&reg; AQ Cartridge: 350 units/0.42 mL (0.42 mL) [contains benzyl alcohol, neomycin (may have trace amounts), streptomycin (may have trace amounts), sucrose 50 mg/mL; delivers 300 units]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Follistim&reg; AQ Cartridge: 650 units/0.78 mL (0.78 mL) [contains benzyl alcohol, neomycin (may have trace amounts), streptomycin (may have trace amounts), sucrose 50 mg/mL; delivers 600 units]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Follistim&reg; AQ Cartridge: 975 units/1.17 mL (1.17 mL) [contains benzyl alcohol, neomycin (may have trace amounts), streptomycin (may have trace amounts), sucrose 50 mg/mL; delivers 900 units]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3882689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F242597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Follistim&reg; AQ: Administered by I.M. or SubQ injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Follistim&reg; AQ Cartridge: Follistim&reg; AQ cartridge may be administered only by SubQ injection using the Follistim Pen&reg; which can be set to deliver the appropriate dose.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F242596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Females: Induction of ovulation and pregnancy in anovulatory infertile patients in whom the cause of infertility is functional and not caused by primary ovarian failure; induction of pregnancy in normal ovulatory women undergoing Assisted Reproductive Technology (ART) (eg,",
"     <i>",
"      in vitro",
"     </i>",
"     fertilization [IVF], intracytoplasmic sperm injection [ICSI])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Males: Induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3882698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency may vary based on indication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache (7%), fatigue (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne (7%), rash (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Pelvic discomfort (8%), ovarian hyperstimulation (6% to 8%), pelvic pain (6%), gynecomastia (3%), ovarian cyst (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea (4%), abdominal pain/discomfort (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site pain (7%), injection site reaction (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Abdominal distension, breast tenderness, constipation, diarrhea, metrorrhagia, miscarriage, ovarian enlargement, ovarian neoplasm, ovarian torsion, thromboembolism, vaginal hemorrhage",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F242599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to follitropins or any component of the formulation; high levels of FSH indicating primary gonadal failure; uncontrolled nongonadal endocrinopathies (eg, adrenal, pituitary, or thyroid disorders); tumor of the ovary, breast, uterus, testis, hypothalamus, or pituitary gland",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Females: Additional contraindications: Abnormal vaginal bleeding of undetermined origin; ovarian cysts or enlargement not due to polycystic ovary syndrome; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F242592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian enlargement: If ovaries are abnormally enlarged on the last day of treatment, withhold hCG to reduce the risk of ovarian hyperstimulation syndrome (OHSS).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian hyperstimulation syndrome (OHSS): OHSS is characterized by severe ovarian enlargement, abdominal pain/distention, nausea, vomiting, diarrhea, dyspnea, and oliguria, and may be accompanied by ascites, pleural effusion, hypovolemia, electrolyte imbalance, hemoperitoneum, and thromboembolic events. If hyperstimulation occurs, stop treatment and hospitalize patient. This syndrome develops rapidly within 24 hours to several days and generally occurs after treatment has ended and reaches its maximum on days 7-10 following treatment. Hemoconcentration associated with fluid loss into the abdominal cavity has occurred and should be assessed by fluid intake and output, weight, hematocrit, serum and urinary electrolytes, urine specific gravity, BUN and creatinine, and abdominal girth. Determinations should be performed daily or more often if the need arises. Treatment is primarily symptomatic and consists of bedrest, fluid and electrolyte replacement, and analgesics. The ascitic, pleural, and pericardial fluids should not be removed unless needed to relieve symptoms of cardiopulmonary distress.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian torsion: May occur in relation to OHSS, pregnancy, previous or current ovarian cyst and polycystic ovaries, previous abdominal surgery, and previous history of ovarian torsion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary effects: Serious pulmonary conditions (atelectasis, acute respiratory distress syndrome, and exacerbation of asthma) have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolic events: In association with and separate from ovarian hyperstimulation syndrome, thromboembolic events have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neomycin: May contain trace amounts of neomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Streptomycin: May contain trace amounts of streptomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: To minimize risks, use only at the lowest effective dose. Monitor ovarian response with serum estradiol and vaginal ultrasound on a regular basis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician: These medications should only be used by physicians who are thoroughly familiar with infertility problems and their management.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Multiple births: May result from the use of these medications; advise patient of the potential risk of multiple births before starting the treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3882691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13688046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Ectopic pregnancies, congenital abnormalities, and multiple births have been reported. The incidence of congenital abnormality may be slightly higher after ART than with spontaneous conception; higher incidence may be related to parenteral characteristics (maternal age, sperm characteristics). Follitropin Beta is used for the induction of ovulation; use is contraindicated in women who are already pregnant.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3882694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16355475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if follitropin beta is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F4370387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Follistim AQ Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 units/0.5 mL (0.5 mL): $124.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 units/0.5 mL (0.5 mL): $248.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Follistim AQ Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 units/0.36 mL (0.42 mL): $496.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 units (0.78 mL): $993.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     900 units/1.08 mL (1.17 mL): $1490.53",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3882737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females: Monitor sufficient follicular maturation. This may be directly estimated by sonographic visualization of the ovaries and endometrial lining or measuring serum estradiol levels. The combination of both ultrasonography and measurement of estradiol levels is useful for monitoring for the growth and development of follicles and timing hCG administration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     The clinical evaluation of estrogenic activity (changes in vaginal cytology and changes in appearance and volume of cervical mucus) provides an indirect estimate of the estrogenic effect upon the target organs and, therefore, it should only be used adjunctively with more direct estimates of follicular development (ultrasonography and serum estradiol determinations).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     The clinical confirmation of ovulation is obtained by direct and indirect indices of progesterone production. The indices most generally used are: rise in basal body temperature, increase in serum progesterone, and menstruation following the shift in basal body temperature.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Monitor for signs and symptoms of OHSS for at least 2 weeks following hCG administration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Males: Monitor for sufficient spermatogenesis. This can be directly estimated by semen analysis, or indirectly estimated by serum testosterone level.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4301370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Puregon (AR, AT, BE, BR, CH, CL, CN, CO, CZ, DE, DK, FR, GB, GR, HK, HN, ID, IE, IL, IT, MX, MY, NL, NO, PE, PH, PK, PL, PT, SE, SG, TH, TW, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F242590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Follitropin beta is a human FSH preparation of recombinant DNA origin. Follitropins stimulate ovarian follicular growth in women who do not have primary ovarian failure and stimulate spermatogenesis in men with hypogonadotrophic hypogonadism. FSH is required for normal follicular growth, maturation, gonadal steroid production, and spermatogenesis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3882727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Peak effect: Females: Follicle development: Within cycle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Females: I.M.: 76%; SubQ: 78%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Females: 8 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Females: I.M.: 44 hours (single dose), 27-30 hours (multiple doses); SubQ: 33 hours (single dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: Females: SubQ: 13 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dickey RP, Thornton M, Nichols J, et al, &ldquo;Comparison of the Efficacy and Safety of a Highly Purified Human Follicle-Stimulating Hormone (Bravelle) and Recombinant Follitropin-Beta for",
"      <i>",
"       in vitro",
"      </i>",
"      Fertilization: A Prospective, Randomized Study,&rdquo;",
"      <i>",
"       Fertil Steril",
"      </i>",
"      , 2002, 77(6):1202-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/52/5958/abstract-text/12057729/pubmed\" id=\"12057729\" target=\"_blank\">",
"        12057729",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Petak SM, Nankin HR, Spark RF, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients -- 2002 Update,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2002, 8(6):440-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/52/5958/abstract-text/15260010/pubmed\" id=\"15260010\" target=\"_blank\">",
"        15260010",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Practice Committee of American Society for Reproductive Medicine, \"Use of Exogenous Gonadotropins in Anovulatory Women: A Technical Bulletin,\"",
"      <i>",
"       Fertil Steril",
"      </i>",
"      , 2008, 90(5 Suppl):7-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/52/5958/abstract-text/19007651/pubmed\" id=\"19007651\" target=\"_blank\">",
"        19007651",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Williams RS, Vensel T, Sistrom CL, et al, &ldquo;Pregnancy Rates in Varying Age Groups After",
"      <i>",
"       in vitro",
"      </i>",
"      Fertilization: A Comparison of Follitropin Alfa (Gonal F) and Follitropin Beta (Follistim),&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2003, 189(2):342-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/52/5958/abstract-text/14520188/pubmed\" id=\"14520188\" target=\"_blank\">",
"        14520188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8945 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-109.230.63.219-37932DBF7B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_52_5958=[""].join("\n");
var outline_f5_52_5958=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882687\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3888770\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882690\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882734\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896269\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896270\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242595\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882689\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242597\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242596\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882698\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242599\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242592\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299361\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220490\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882691\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13688046\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882694\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16355475\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4370387\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882737\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4301370\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242590\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882727\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8945\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8945|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/28/30148?source=related_link\">",
"      Follitropin beta (recombinant human follicle stimulating hormone): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_52_5959="ECG - Dilated cardiomyopathy in 13 yo boy";
var content_f5_52_5959=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 606px\">",
"   <div class=\"ttl\">",
"    Electrocardiogram of 13-year-old boy with dilated cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 586px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram demonstrating increased QRS voltage with ST segment and T wave abnormalities in a 13-year-old boy with dilated cardiomyopathy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_52_5959=[""].join("\n");
var outline_f5_52_5959=null;
var title_f5_52_5960="Intertriginous erythrasma";
var content_f5_52_5960=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51713%7EDERM%2F62143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51713%7EDERM%2F62143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythrasma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 311px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clinical image of red-brown plaques of erythrasma in the groin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. John L. Aeling.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythrasma under light from a Wood's lamp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Examination with a Wood's lamp reveals coral red fluorescence in this patient with erythrasma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_52_5960=[""].join("\n");
var outline_f5_52_5960=null;
var title_f5_52_5961="Indications for red cell transfusion in the adult";
var content_f5_52_5961=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Indications for red cell transfusion in the adult",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/52/5961/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/52/5961/contributors\">",
"     Steven Kleinman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/52/5961/contributors\">",
"     Jeffrey L Carson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/52/5961/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/52/5961/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/52/5961/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/52/5961/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/52/5961/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For many decades, the decision to transfuse red blood cells was based upon the",
"    <span class=\"nowrap\">",
"     \"10/30",
"    </span>",
"    rule\": transfusion was indicated in all patients in order to maintain a blood hemoglobin concentration above 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (100",
"    <span class=\"nowrap\">",
"     g/L)",
"    </span>",
"    and a hematocrit above 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/1\">",
"     1",
"    </a>",
"    ]. However, concern regarding transmission of blood-borne pathogens and efforts at cost containment caused a reexamination of transfusion practices in the 1980s. The 1988 National Institutes of Health Consensus Conference on Perioperative Red Blood Cell Transfusions suggested that no single criterion should be used as an indication for red cell component therapy and that multiple factors related to the patient's clinical status and oxygen delivery needs should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/2\">",
"     2",
"    </a>",
"    ]. Accordingly, the decision to transfuse erythrocytes must be based upon an assessment of the risks of anemia versus the risks of transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The indications for red cell transfusion will be reviewed here. General aspects of red cell collection, storage, and safety as well as the use of massive blood transfusion and blood salvage procedures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=see_link\">",
"     \"Use of red blood cells for transfusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link\">",
"     \"Laboratory testing of donated blood\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link\">",
"     \"Massive blood transfusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10582?source=see_link\">",
"     \"Intraoperative and postoperative blood salvage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preoperative autologous donation of red cells is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12134?source=see_link\">",
"     \"Preoperative autologous blood donation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31605?source=see_link\">",
"     \"Controversial areas in preoperative autologous blood donation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of massive amounts of blood as well as the use of blood in the critically ill are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link\">",
"     \"Massive blood transfusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/49/793?source=see_link\">",
"     \"Use of blood products in the critically ill\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY OF ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major physiologic considerations relevant to anemic patients are the degree to which oxygen delivery to the tissues is adequate and compensatory mechanisms for maintaining oxygen delivery will not become overwhelmed or deleterious [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31430?source=see_link\">",
"     \"Oxygen delivery and consumption\"",
"    </a>",
"    .) Oxygen delivery (DO2) is determined by the formula:",
"   </p>",
"   <p>",
"    DO2 &nbsp;= &nbsp;Cardiac output &nbsp;x &nbsp;arterial oxygen content",
"   </p>",
"   <p>",
"    The arterial oxygen content consists of both hemoglobin-bound oxygen and, to a much lesser extent, dissolved oxygen. Thus:",
"   </p>",
"   <p>",
"    DO2 &nbsp;= &nbsp;Cardiac output &nbsp;x &nbsp;[(1.39 &nbsp;x &nbsp;[Hb] &nbsp;x &nbsp;arterial oxygen saturation) + &nbsp;(PaO2 &nbsp;x 0.0031)]",
"   </p>",
"   <p>",
"    In critically ill patients, oxygen utilization may become pathologically dependent upon DO2; elevated arterial lactate concentrations and a change in the slope of the oxygen extraction ratio may be noted as this occurs. An elevated arterial lactate, an oxygen extraction ratio of greater than 0.3 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/5\">",
"     5",
"    </a>",
"    ], and a DO2 of less than 10 to 12",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per minute are each indicators of poor tissue perfusion, and attempts should be made to increase DO2 by red cell transfusion, improvement of oxyhemoglobin saturation, or augmentation of cardiac output. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At rest, there is a large redundancy in oxygen delivery, since the rate of delivery normally exceeds consumption by a factor of four. Thus, if intravascular volume is maintained during bleeding and cardiovascular status is not impaired, oxygen delivery theoretically will be adequate until the hematocrit falls below 10 percent because greater cardiac output, rightward shift of the oxygen-hemoglobin dissociation curve, and increased oxygen extraction can compensate for the decrease in arterial oxygen content (",
"    <a class=\"graphic graphic_table graphicRef68984 \" href=\"UTD.htm?1/42/1707\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These predictions were confirmed in a study in which healthy resting humans underwent acute isovolemic reduction in the hemoglobin to 5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (equivalent to a hematocrit of about 15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/6\">",
"     6",
"    </a>",
"    ]. There was no evidence of inadequate oxygen delivery, since the fall in hemoglobin was associated with progressive increases in stroke volume and heart rate (and therefore cardiac output) and a progressive reduction in the systemic vascular resistance. Heart rate was found to increase linearly in response to the acute isovolemic anemia, and could be described by the following formula [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Heart rate",
"    <span class=\"nowrap\">",
"     (beats/min)",
"    </span>",
"    = 116 &nbsp;- &nbsp;4.0 x Hgb",
"    <span class=\"nowrap\">",
"     (g/dL)",
"    </span>",
"   </p>",
"   <p>",
"    The preceding considerations represent the optimal clinical response. In practice, red cell transfusions should be initiated when the patient develops symptoms of anemia (eg, easy fatigue, dyspnea on exertion, tachycardia), regardless of the degree of anemia. The level at which this occurs varies with age and underlying disease. Young patients may not develop symptoms until the hematocrit drops below 20 percent, a level that would be poorly tolerated by most older patients. A hematocrit of at least 25 percent, and perhaps as high as 33 percent, is preferred in patients with significant underlying cardiovascular disease. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Cardiovascular disease and myocardial infarction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    While there is concern that compensatory mechanisms may be impaired in critically ill patients, thereby justifying prophylactic transfusion to a hemoglobin of 10",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    data in favor of this approach are sparse. As an example, a multicenter study of 838 critically ill patients found no difference in mortality between patients randomly assigned to a transfusion strategy designed to maintain hemoglobin at either 7 to 9 or 10 to 12",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL SITUATIONS REQUIRING RED CELL TRANSFUSION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Transfusion in the perioperative or intensive care unit setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Criteria have been proposed for red cell transfusion in perioperative or intensive care unit settings, which are generally not recommended when the hemoglobin is &ge;10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (100",
"    <span class=\"nowrap\">",
"     g/L)",
"    </span>",
"    in otherwise healthy subjects, but should be given when the hemoglobin is less than 7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/2\">",
"     2",
"    </a>",
"    ]. A number of studies have indicated that these guidelines have generally been followed for such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective survey of almost 9000 patients who underwent surgery for hip fracture found a high degree of adherence to these recommendations. Transfusions were given to 95 percent of patients with a hemoglobin below 7",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      versus only 6.6 percent of those with a hemoglobin &ge;10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/9\">",
"       9",
"      </a>",
"      ]. There was greater variability at hemoglobin concentrations between 7 and 9.9",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      as 56 percent of such patients were transfused. Receipt of red cell transfusions did not influence mortality in patients with hemoglobin concentrations of 8",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or greater.",
"     </li>",
"     <li>",
"      A retrospective observational study was also conducted of red cell transfusion practice between 1997 and 2007 in 3533 patients without evidence of acute coronary syndromes, hemorrhage, or hemoglobinopathy admitted to the medical intensive care unit of a large academic medical center [",
"      <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/10\">",
"       10",
"      </a>",
"      ]. During this period, the mean nadir hemoglobin levels for nontransfused patients decreased from 11.2 to 10.4",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      while the mean nadir hemoglobin levels for transfused patients decreased from 7.9 to 7.3",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      These practice changes were not accounted for by changes in patient characteristics and likely reflect implementation of the more restrictive transfusion strategy of the TRICC trial discussed below.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Optimal transfusion level",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal level at which perioperative blood transfusion should be given is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/12\">",
"     12",
"    </a>",
"    ]. Both lower (hemoglobin &le;6",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    and higher (hematocrit of 30 percent in healthy subjects) values have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Two randomized trials shed some light on this issue:",
"   </p>",
"   <p>",
"    The TRICC (Transfusion Requirements in Critical Care) trial randomly assigned 418 critically ill euvolemic patients to a \"restrictive\" transfusion strategy (ie, red cells transfused for Hgb concentration &lt;7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and Hgb maintained at 7 to 9",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    and 420 patients to a \"liberal\" strategy (red cells transfused for Hgb &lt;10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and Hgb maintained at 10 to 12",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/8\">",
"     8",
"    </a>",
"    ]. Mortality rates were significantly lower with the restrictive strategy among patients who were less severely ill (APACHE II score &le;20; 9 versus 16 percent) and among patients &lt;55 years of age (6 versus 13 percent), but not among patients with clinically significant cardiac disease (20 versus 23 percent).",
"   </p>",
"   <p>",
"    The overall mortality rate during hospitalization was significantly lower in the restrictive strategy group (22 versus 28 percent), although 30-day mortality was similar. These results suggest that a restrictive strategy of red cell transfusion is at least as effective as, and possibly superior to, a liberal transfusion strategy in critically ill patients, with the possible exception of patients with acute myocardial infarction and unstable angina (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Cardiovascular disease and myocardial infarction'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The second trial randomly assigned 428 consecutive patients undergoing coronary artery bypass grafting (CABG) to a study group (212 patients) which received a red blood cell (RBC) transfusion postoperatively at a hemoglobin concentration &lt;8",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    or a control group (216 patients) transfused per clinical judgment and institutional guidelines (Hgb &lt;9",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/15\">",
"     15",
"    </a>",
"    ]. Appropriate exclusions were made for preoperative conditions in both groups and hemodynamic instability in the study group.",
"   </p>",
"   <p>",
"    There was no difference in morbidity, mortality, or self-assessment for fatigue or anemia between the two groups. Postoperative transfusion rates were significantly lower for the study group (0.9 versus 1.4 RBC",
"    <span class=\"nowrap\">",
"     units/patient),",
"    </span>",
"    amounting to a savings of 500 RBC units per 1000 CABG patients for the more restrictive study group.",
"   </p>",
"   <p>",
"    The deleterious effect of severe postoperative anemia on mortality was shown in a study of 300 patients with a postoperative hemoglobin (Hgb) concentration &le;8.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    who refused blood transfusion for religious reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/16\">",
"     16",
"    </a>",
"    ]. While a hemoglobin between 7 and 8",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    appeared to have no immediate adverse effect on mortality, there was a clear risk of death in the post-operative period when the hemoglobin fell below 7",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    In this study, 30-day in-hospital mortality for patients with various postoperative hemoglobin levels was:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hgb 7.1 to 8.0 (n = 99) &mdash; zero percent",
"     </li>",
"     <li>",
"      Hgb 5.1 to 7.0 (n = 110) &mdash; 9 percent",
"     </li>",
"     <li>",
"      Hgb 3.1 to 5.0 (n = 60) &mdash; 30 percent",
"     </li>",
"     <li>",
"      Hgb &le;3.0 (n = 31) &mdash; 64 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A somewhat different conclusion was reached in a retrospective study of 10,179 initially non-anemic patients undergoing on-pump cardiac surgery in an academic setting. Results included [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no statistically significant increased risk of an adverse outcome (ie, stroke, kidney failure, death) for subjects who developed a nadir intraoperative hemoglobin &lt;7.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (OR 1.15; 95% CI 0.84-1.56).",
"     </li>",
"     <li>",
"      In contrast, there was an increased risk of an adverse outcome, as defined above, for those subjects who had an intraoperative decrease in their hemoglobin concentration (from preoperative levels) of greater than 50 percent (OR 1.53; 95% CI 1.12-2.08).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The conclusion that the risk for an adverse outcome was related to the relative intraoperative reduction in hemoglobin, rather than the hemoglobin nadir itself, needs to be confirmed in other studies and other settings before transfusion practice is changed to reflect this finding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Patients with cardiovascular disease or risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of the \"optimal\" transfusion level for perioperative patients with cardiovascular disease or cardiovascular risk factors was examined in the Transfusion Trigger Trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS trial). Eligible patients &ge;50 years of age with a Hb concentration &lt;10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    within three days after surgery were randomly assigned to one of two transfusion strategies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liberal transfusion group &mdash; Immediate transfusion of one unit of packed RBCs plus enough subsequent RBCs to raise the Hb level to &gt;10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      at any time during the hospitalization when the Hb level fell below 10",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"     </li>",
"     <li>",
"      Restrictive or symptomatic transfusion group &mdash; Patients received single unit transfusions only if they develop symptoms of anemia or, in the absence of symptoms, or at physician discretion, when the Hb level fell below 8",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary outcome of the study was death or an inability to walk 10 feet, or across a room, without human assistance at the 60-day follow-up. Secondary outcomes included mortality and the combined outcome of in-hospital myocardial infarction, unstable angina, or death for any reason. Results in the 2016 enrolled subjects (mean age 81.6 years, range: 41 to 103) included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rates of the primary outcome were similar in the liberal and restrictive transfusion groups (35.2 versus 34.7 percent, respectively; OR 1.01; 95% CI 0.84-1.22).",
"     </li>",
"     <li>",
"      The rates of in-hospital acute coronary syndrome or death for the liberal and restrictive groups were similar at 4.3 and 5.2 percent, respectively (OR 0.82; 99% CI 0.48-1.42). The rates of death on 60-day follow-up were also similar at 7.6 and 6.6 percent, respectively (OR 1.17; 99% CI 0.75-1.83).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Results of this study suggest that it is reasonable to withhold transfusion in patients who have undergone surgery in the absence of symptoms of anemia or in the absence of a decline in the hemoglobin level below 8",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    even in elderly patients with underlying cardiovascular disease or cardiovascular risk factors. A Cochrane review of 19 trials has supported the use of restrictive transfusion triggers in most patients, including those with pre-existing cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14026631\">",
"    <span class=\"h3\">",
"     Patients with acute upper gastrointestinal bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our approach to transfusion in this setting is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link&amp;anchor=H5079586#H5079586\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'Blood transfusions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4502863\">",
"    <span class=\"h3\">",
"     Potential risks of transfusion in the surgical setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the risks of blood transfusion present in all settings (eg, circulatory overload, infection, transfusion reactions), a longitudinal, uncontrolled observational study concluded that minimal amounts of red cell transfusion in the intraoperative setting may be associated with an increase in morbidity and mortality, for reasons that are poorly understood but may include transfusion-related immunosuppression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link&amp;anchor=H6#H6\">",
"     \"Leukoreduction to prevent complications of blood transfusion\", section on 'Immunosuppression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Use of supplemental erythropoietin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythropoietin (EPO) increases erythropoiesis provided that stores of vitamin B12, folate, and iron are adequate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16890?source=see_link\">",
"     \"Introduction to recombinant hematopoietic growth factors\"",
"    </a>",
"    .) As an example, EPO is standard therapy for the anemia of renal failure, and its use has markedly reduced the need for red cell transfusions in this group of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is possible to reduce the need for red blood cell transfusion in the postoperative setting if the patient is treated preoperatively with recombinant human EPO and supplemental iron with or without operative blood salvage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    autologous blood donation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. As an example, in a multicenter study, 201 patients undergoing total hip joint arthroplasty were randomly assigned to receive treatment with four weekly doses of EPO at high dose (40,000 units), low dose (20,000 units), or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/21\">",
"     21",
"    </a>",
"    ]. All received iron supplementation (450",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    PO) for 42 or more days before surgery. Compared with the placebo-treated group (45 percent transfusion rate), blood transfusion was required significantly less often in patients assigned to the high or low-dose EPO groups (11 and 23 percent, respectively).",
"   </p>",
"   <p>",
"    EPO given postoperatively to anemic patients can increase the rate of recovery to normal hemoglobin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/24\">",
"     24",
"    </a>",
"    ]. However, neither the efficacy, safety, nor the cost-effectiveness of its use in critically ill patients has been adequately determined [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. At present, use of EPO cannot be recommended in an attempt to reduce transfusion requirements in the ICU.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cardiovascular disease and myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies evaluating the importance of anemia and the role of transfusion in the setting of an acute coronary syndrome (ie, unstable angina, myocardial infarction) have reached differing conclusions. This important and controversial subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction\", section on 'Blood transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although anemia occurs frequently in patients with heart failure, limited data are available on treatment of anemia in this population. General indications for red cell transfusion may be applied to patients with HF; however careful attention to volume status is indicated when transfusion is required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1705?source=see_link\">",
"     \"Impact of anemia in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Avoiding hyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion-related hyperkalemia can be minimized by selecting blood collected less than five days prior to transfusion. A better alternative for removing extracellular potassium from stored red cells is to wash the unit with saline immediately before infusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=see_link&amp;anchor=H9#H9\">",
"     \"Use of red blood cells for transfusion\", section on 'Potassium leakage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This issue may be especially important in patients with renal failure, infants and children, and in those receiving massive transfusion or previously irradiated blood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27832?source=see_link&amp;anchor=H8#H8\">",
"     \"Red cell transfusion in infants and children: Selection of blood products\", section on 'Irradiated red cells'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link&amp;anchor=H14#H14\">",
"     \"Massive blood transfusion\", section on 'Prevention of hyperkalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chronic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic anemia (eg, bone marrow failure syndromes) may be dependent upon red cell replacement over a period of months of years, which can lead to iron overload. Approximately 200 mg of iron are delivered per unit of RBC; this iron is released when hemoglobin from the transfused RBCs is metabolized after red cell death. Given the progressive loss of red cell viability that occurs during storage, the strategy of selecting the \"freshest-available\" units in order to maximize post-transfusion survival may be optimal but will be dependent on blood center and hospital logistics. This strategy will reduce over time the total number of units the patient will need to receive and therefore reduce the total amount of iron delivered to the patient. Hemosiderosis can produce organ damage when the total iron delivered approaches 15 to 20 grams, the amount of iron in 75 to 100 units of red cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link&amp;anchor=H11#H11\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Transfusional iron overload'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The issue of red cell transfusion in patients with acquired or congenital hemolytic anemia is more complex, and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7802?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of beta thalassemia\", section on 'Chronic hypertransfusion therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of the management of sickle cell disease\", section on 'Transfusion therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Red blood cell transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TRANSFUSION GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion guidelines have been published by the Blood Transfusion Task Force of the British Committee for Standards in Hematology (",
"    <a class=\"graphic graphic_figure graphicRef60721 \" href=\"UTD.htm?25/4/25678\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/27\">",
"     27",
"    </a>",
"    ] and the AABB (formerly the American Association of Blood Banks) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/28\">",
"     28",
"    </a>",
"    ]. Guidelines have also been published for red cell transfusion in adult trauma and critical care patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/49/793?source=see_link&amp;anchor=H2#H2\">",
"     \"Use of blood products in the critically ill\", section on 'Red blood cells'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link&amp;anchor=H10#H10\">",
"     \"Initial evaluation and management of shock in adult trauma\", section on 'Transfusion of red blood cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These guidelines provide an overall, generally accepted framework for transfusion decision making in the anemic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    actively bleeding patient, based upon the physiologic principles discussed above. However, significant gaps in our knowledge concerning when, and when not, to transfuse still exist, especially in patients with underlying cardiac disease. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Cardiovascular disease and myocardial infarction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As an example, the AABB transfusion guidelines include the following four recommendations, with which we concur [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A restrictive transfusion strategy (transfuse at hemoglobin levels at or below 7 to 8",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      is recommended for hospitalized hemodynamically stable patients (strong recommendation, high quality evidence).",
"     </li>",
"     <li>",
"      A restrictive transfusion strategy is suggested in hospitalized patients with preexisting cardiovascular disease. One should consider transfusion for patients with symptoms or a hemoglobin of 8",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or less (weak recommendation, moderate quality evidence).",
"     </li>",
"     <li>",
"      There is insufficient evidence to suggest either a restrictive or liberal transfusion strategy for hospitalized hemodynamically stable patients with the acute coronary syndrome.",
"     </li>",
"     <li>",
"      Transfusion decisions should be influenced by symptoms as well as hemoglobin concentration (weak recommendation, low quality of evidence).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The AABB panel concluded that the evidence was consistent in showing that restrictive transfusion strategy was safe and associated with less blood use than liberal transfusion. The panel&rsquo;s recommendations apply to most medical and surgical patients with the exception of those with acute coronary syndrome. Because trials in intensive care unit patients used a 7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    threshold, this hemoglobin level was recommended as the level below which one should consider transfusion. Whether surgical or medical patients outside the intensive care unit would tolerate this threshold has not been evaluated, and therefore the panel recommended an 8",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    threshold for these patients. Importantly, the panel recommended that transfusion should be considered, but not necessarily administered, at the hemoglobin threshold of 7 to 8",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    The clinical status of the patient should be assessed, and if the patient is stable a transfusion may not be needed.",
"   </p>",
"   <p>",
"    These guidelines provide an overall framework for transfusion decision making in the anemic hemodynamically stable patient based upon the physiologic principles discussed above. However, it is notable that transfusion &ldquo;triggers&rdquo; differ among countries, may depend upon the type of surgery contemplated, and are often disregarded [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/30\">",
"     30",
"    </a>",
"    ]. A review of 450 typical inpatient medical, surgical, or trauma scenarios in which transfusion would be commonly",
"    <span class=\"nowrap\">",
"     considered/used",
"    </span>",
"    was performed by an international multidisciplinary panel of 15 experts [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/31\">",
"     31",
"    </a>",
"    ] who, based on their knowledge and review of pertinent literature, rated whether allogeneic red cell transfusion was appropriate.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Overall, panelists rated allogeneic red cell transfusion as appropriate in only 12 percent of the scenarios.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Red cell transfusion was most often rated as",
"      <strong>",
"       appropriate",
"      </strong>",
"      (81 percent) in scenarios featuring patients with hemoglobin levels &le;7.9",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      associated morbidities, and age &gt;65 years.",
"     </li>",
"     <li>",
"      Red cell transfusion was rated",
"      <strong>",
"       inappropriate",
"      </strong>",
"      in all scenarios featuring patients with hemoglobin levels &ge;10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      and in 71 percent of scenarios featuring patients with hemoglobin levels of 8.0 to 9.9",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, the likelihood of a transfusion being of benefit is high when the patient's hemoglobin is less than 6",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (60",
"    <span class=\"nowrap\">",
"     g/L)",
"    </span>",
"    and is low when it is greater than 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (100",
"    <span class=\"nowrap\">",
"     g/L).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Effect on Hgb and Hct",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each unit of packed cells with a volume of 300 mL contains approximately 200 mL of red cells and, in an adult, will raise the hematocrit (Hct) by roughly 3 to 4 percentage points and the hemoglobin (Hgb) by about 1",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    unless there is continued bleeding. One study in 52 non-bleeding patients confirmed the 1",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    increase in Hgb per unit of red cells transfused (mean 1.0; 95% CI 0.85-1.10) and demonstrated that hemoglobin levels taken at 15 minutes post-transfusion were not significantly different from those taken at 1, 2, or 24 hours post-transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21734298\">",
"    <span class=\"h2\">",
"     Effect on iron indices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current FDA criterion for viability of transfused red cells means that up to 25 percent of the transfused cells may be non-viable and leave the circulation within the first 24 hours following transfusion. As a result, up to 25 percent of the iron in one unit of blood may be returned to the plasma within 24 hours, resulting in changes in the levels of iron, ferritin, and total iron binding capacity. In addition, stored red cells release into the supernatant some of their iron as non-transferrin-bound iron (NTBI) at around 17 days of storage, and the levels of NTBI were found to increase in the blood of some recipients at about two to three weeks post-transfusion, further increasing the return of the transfused iron back into the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=see_link&amp;anchor=H7#H7\">",
"     \"Use of red blood cells for transfusion\", section on 'Red cell viability and recovery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a rule of thumb, iron studies will not reflect this new steady state until at least two to three weeks have elapsed between the time of the last transfusion and measurement of iron, TIBC,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ferritin, although detailed studies addressing this issue are not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Choice of component",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a decision to transfuse has been made, the choice is between red cells (RBC), whole blood (WB) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5961/abstract/35\">",
"     35",
"    </a>",
"    ], or autologous salvaged blood in the operative or post-operative setting. In addition, red cell preparations may be leukoreduced, irradiated, or washed prior to transfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=see_link&amp;anchor=H13#H13\">",
"     \"Use of red blood cells for transfusion\", section on 'Specialized RBC components'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, a patient with chronic anemia should be replaced with red cell preparations containing minimal plasma, since volume replacement is not required. Furthermore, since the patient already has an expanded blood volume to compensate for the anemia, congestive failure may be a risk if plasma is also given. Whole blood should be considered only when dealing with an adult who has bled acutely and massively and then only after the patient has received approximately five to seven units of red cells plus crystalloids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link\">",
"     \"Massive blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Leukoreduced red cell preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukoreduced products are more costly but are indicated in potential transplant recipients, patients with previous transfusion reactions, patients undergoing cardiovascular surgery, and cytomegalovirus (CMV) seronegative at-risk patients for whom seronegative components are not available. They should also be considered in chronically transfused patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link\">",
"     \"Leukoreduction to prevent complications of blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Reinfusion of autologous red cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous blood collecting devices allow for rapid transfusion of immense quantities of autologous blood collected via chest tubes or aspirated from the pleural and peritoneal cavities, thereby reducing the need for allogeneic products. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10582?source=see_link\">",
"     \"Intraoperative and postoperative blood salvage\"",
"    </a>",
"    .) This technique may be particularly valuable for the patients with antibodies which preclude the use of crossmatch-compatible blood; it is also considered acceptable by some Jehovah's Witnesses, provided that the blood does not leave the bedside for processing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10986?source=see_link&amp;anchor=H6#H6\">",
"     \"The approach to the patient who refuses blood transfusion\", section on 'Jehovah's Witnesses'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Autotransfusion systems damage cells to some degree, and limitation of autotransfusion to less than 10 to 15 liters is recommended when possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Use of premedication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible uses of premedication and other techniques in an attempt to prevent febrile nonhemolytic transfusion reactions (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antihistamines) or transfusion-associated volume overload (eg, diuretics, reductions in the rate of transfusion) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link&amp;anchor=H6#H6\">",
"     \"Immunologic blood transfusion reactions\", section on 'Acetaminophen and antihistamine premedication'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=see_link&amp;anchor=H2#H2\">",
"     \"Transfusion reactions caused by chemical and physical agents\", section on 'Transfusional volume overload (TACO)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PATIENTS UNWILLING OR UNABLE TO BE TRANSFUSED",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients refuse allogeneic red cell transfusion for religious or other reasons (eg, fear of transfusion-related infection or other side effects). Others may be unable to be transfused because of unavailability of compatible blood. Management of such patients, especially those with active bleeding, or who may require surgery or chemotherapy, can be extraordinarily difficult. This subject is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10986?source=see_link\">",
"     \"The approach to the patient who refuses blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/4/29762?source=see_link\">",
"       \"Patient information: When your cancer treatment makes you tired (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/52/22338?source=see_link\">",
"       \"Patient information: Blood donation (giving blood) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26820?source=see_link\">",
"       \"Patient information: Blood donation and transfusion (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27123843\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is excellent clinical trial evidence that suggests that a restrictive transfusion policy should guide transfusion decisions in most patients. We recommend following the AABB transfusion guidelines. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Transfusion guidelines'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In hemodynamically stable intensive care unit patients, we recommend transfusion if the patient&rsquo;s hemoglobin level is less than 7",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In hemodynamically stable medical and surgical patients, we suggest transfusion if the patient&rsquo;s hemoglobin is less than 8",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or if the patient has symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      All patients should be assessed clinically when transfusion is considered. If the patient is stable, transfusion may not be needed even when hemoglobin level is 7 to 8",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who are rapidly bleeding or hemodynamically unstable, transfusion should be based on clinical judgment and volume status.",
"     </li>",
"     <li>",
"      Each unit of packed cells will raise the hematocrit by roughly 3 to 4 percentage points and the hemoglobin by about 1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (10",
"      <span class=\"nowrap\">",
"       g/L),",
"      </span>",
"      unless there is continued bleeding. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Effect on Hgb and Hct'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for the use of leukoreduced blood products are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link\">",
"       \"Leukoreduction to prevent complications of blood transfusion\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Management of patients unwilling or unable to be transfused with red cells is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10986?source=see_link\">",
"       \"The approach to the patient who refuses blood transfusion\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H763681\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate would like to acknowledge Addison K May, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/1\">",
"      Wang JK, Klein HG. Red blood cell transfusion in the treatment and management of anaemia: the search for the elusive transfusion trigger. Vox Sang 2010; 98:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/2\">",
"      Consensus conference. Perioperative red blood cell transfusion. JAMA 1988; 260:2700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/3\">",
"      Proceedings of the Blood Management Practice Guidelines Conference. Am J Surg 1995; 170(Suppl):6A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/4\">",
"      Kleinman S, Marshall D, AuBuchon J, Patton M. Survival after transfusion as assessed in a large multistate US cohort. Transfusion 2004; 44:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/5\">",
"      Orlov D, O'Farrell R, McCluskey SA, et al. The clinical utility of an index of global oxygenation for guiding red blood cell transfusion in cardiac surgery. Transfusion 2009; 49:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/6\">",
"      Weiskopf RB, Viele MK, Feiner J, et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA 1998; 279:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/7\">",
"      Weiskopf RB, Feiner J, Hopf H, et al. Heart rate increases linearly in response to acute isovolemic anemia. Transfusion 2003; 43:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/8\">",
"      H&eacute;bert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/9\">",
"      Carson JL, Duff A, Berlin JA, et al. Perioperative blood transfusion and postoperative mortality. JAMA 1998; 279:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/10\">",
"      Netzer G, Liu X, Harris AD, et al. Transfusion practice in the intensive care unit: a 10-year analysis. Transfusion 2010; 50:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/11\">",
"      Vuille-Lessard E, Boudreault D, Girard F, et al. Red blood cell transfusion practice in elective orthopedic surgery: a multicenter cohort study. Transfusion 2010; 50:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/12\">",
"      Weiskopf RB. Do we know when to transfuse red cells to treat acute anemia? Transfusion 1998; 38:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/13\">",
"      Practice Guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 1996; 84:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/14\">",
"      Valeri CR, Crowley JP, Loscalzo J. The red cell transfusion trigger: has a sin of commission now become a sin of omission? Transfusion 1998; 38:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/15\">",
"      Bracey AW, Radovancevic R, Riggs SA, et al. Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome. Transfusion 1999; 39:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/16\">",
"      Carson JL, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion 2002; 42:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/17\">",
"      Karkouti K, Wijeysundera DN, Yau TM, et al. The influence of baseline hemoglobin concentration on tolerance of anemia in cardiac surgery. Transfusion 2008; 48:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/18\">",
"      Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med 2011; 365:2453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/19\">",
"      Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2012; 4:CD002042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/20\">",
"      Goldberg MA. Erythropoiesis, erythropoietin, and iron metabolism in elective surgery: preoperative strategies for avoiding allogeneic blood exposure. Am J Surg 1995; 170:37S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/21\">",
"      Feagan BG, Wong CJ, Kirkley A, et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med 2000; 133:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/22\">",
"      Cuenca J, Garc&iacute;a-Erce JA, Mart&iacute;nez F, et al. Perioperative intravenous iron, with or without erythropoietin, plus restrictive transfusion protocol reduce the need for allogeneic blood after knee replacement surgery. Transfusion 2006; 46:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/23\">",
"      Wong CJ, Vandervoort MK, Vandervoort SL, et al. A cluster-randomized controlled trial of a blood conservation algorithm in patients undergoing total hip joint arthroplasty. Transfusion 2007; 47:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/24\">",
"      Atabek U, Alvarez R, Pello MJ, et al. Erythropoetin accelerates hematocrit recovery in post-surgical anemia. Am Surg 1995; 61:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/25\">",
"      Corwin HL, Gettinger A, Pearl RG, et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 2002; 288:2827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/26\">",
"      Carson JL. Should patients in intensive care units receive erythropoietin? JAMA 2002; 288:2884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/27\">",
"      Murphy MF, Wallington TB, Kelsey P, et al. Guidelines for the clinical use of red cell transfusions. Br J Haematol 2001; 113:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/28\">",
"      Carson JL, Grossman BJ, Kleinman S, et al. Red blood cell transfusion: a clinical practice guideline from the AABB*. Ann Intern Med 2012; 157:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/29\">",
"      Napolitano LM, Kurek S, Luchette FA, et al. Clinical practice guideline: red blood cell transfusion in adult trauma and critical care. Crit Care Med 2009; 37:3124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/30\">",
"      Shander A, Van Aken H, Colomina MJ, et al. Patient blood management in Europe. Br J Anaesth 2012; 109:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/31\">",
"      Shander A, Fink A, Javidroozi M, et al. Appropriateness of allogeneic red blood cell transfusion: the international consensus conference on transfusion outcomes. Transfus Med Rev 2011; 25:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/32\">",
"      Wiesen AR, Hospenthal DR, Byrd JC, et al. Equilibration of hemoglobin concentration after transfusion in medical inpatients not actively bleeding. Ann Intern Med 1994; 121:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/33\">",
"      Marwah SS, Blann A, Harrison P, et al. Increased non-transferrin bound iron in plasma-depleted SAG-M red blood cell units. Vox Sang 2002; 82:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/34\">",
"      Grosse R, Lund U, Caruso V, et al. Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major. Ann N Y Acad Sci 2005; 1054:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5961/abstract/35\">",
"      Counts RB, Haisch C, Simon TL, et al. Hemostasis in massively transfused trauma patients. Ann Surg 1979; 190:91.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7948 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-C1F21EE0D5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_52_5961=[""].join("\n");
var outline_f5_52_5961=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27123843\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGY OF ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL SITUATIONS REQUIRING RED CELL TRANSFUSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Transfusion in the perioperative or intensive care unit setting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Optimal transfusion level",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Patients with cardiovascular disease or risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14026631\">",
"      - Patients with acute upper gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4502863\">",
"      - Potential risks of transfusion in the surgical setting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Use of supplemental erythropoietin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cardiovascular disease and myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Avoiding hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chronic anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TRANSFUSION GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Effect on Hgb and Hct",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21734298\">",
"      Effect on iron indices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Choice of component",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Leukoreduced red cell preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Reinfusion of autologous red cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Use of premedication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PATIENTS UNWILLING OR UNABLE TO BE TRANSFUSED",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27123843\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H763681\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7948\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7948|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/4/25678\" title=\"figure 1\">",
"      Red blood cell transfusion in acute bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7948|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/42/1707\" title=\"table 1\">",
"      Oxygen delivery in anemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31605?source=related_link\">",
"      Controversial areas in preoperative autologous blood donation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1705?source=related_link\">",
"      Impact of anemia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=related_link\">",
"      Initial evaluation and management of shock in adult trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10582?source=related_link\">",
"      Intraoperative and postoperative blood salvage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16890?source=related_link\">",
"      Introduction to recombinant hematopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=related_link\">",
"      Massive blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=related_link\">",
"      Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31430?source=related_link\">",
"      Oxygen delivery and consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/52/22338?source=related_link\">",
"      Patient information: Blood donation (giving blood) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26820?source=related_link\">",
"      Patient information: Blood donation and transfusion (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/4/29762?source=related_link\">",
"      Patient information: When your cancer treatment makes you tired (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12134?source=related_link\">",
"      Preoperative autologous blood donation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27832?source=related_link\">",
"      Red cell transfusion in infants and children: Selection of blood products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10986?source=related_link\">",
"      The approach to the patient who refuses blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=related_link\">",
"      Transfusion reactions caused by chemical and physical agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=related_link\">",
"      Treatment of autoimmune hemolytic anemia: Warm agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7802?source=related_link\">",
"      Treatment of beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/49/793?source=related_link\">",
"      Use of blood products in the critically ill",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=related_link\">",
"      Use of red blood cells for transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_52_5962="Management of Crotalinae (rattlesnake, water moccasin [cottonmouth], or copperhead) bites in the United States";
var content_f5_52_5962=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of Crotalinae (rattlesnake, water moccasin [cottonmouth], or copperhead) bites in the United States",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/52/5962/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/52/5962/contributors\">",
"     Allen C Cheng, MB, BS, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/52/5962/contributors\">",
"     Steven A Seifert, MD, FAACT, FACMT",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/52/5962/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/52/5962/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/52/5962/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/52/5962/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/52/5962/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/52/5962/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/52/5962/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Snake bites are a significant problem in the United States. Successful treatment requires prompt definitive medical evaluation, careful clinical assessment, and timely administration of antivenom in selected patients. Consultation with a medical toxicologist or other physician with experience in managing poisonous snake bites is recommended prior to antivenom administration. Phone consultation with a medical toxicologist is available through a United States regional poison control center by calling 1-800-222-1222.",
"   </p>",
"   <p>",
"    The clinical evaluation and management of poisonous Crotalinae (rattlesnake, water moccasin [cottonmouth] or copperhead) snake bites is reviewed here. The principles of management of coral snake bites and snake bites outside the United States are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/48/775?source=see_link\">",
"     \"Management of Elapidae (coral snake) bites in the United States\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31431?source=see_link\">",
"     \"Principles of snake bite management worldwide\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H628739\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rattlesnakes, water moccasins (cottonmouths), and copperheads are members of the family Viperidae, subfamily Crotalinae (formerly Crotalidae). They are also commonly called pit vipers, a name that refers to the heat sensing pit located behind the nostrils.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rattlesnakes, water moccasins (cottonmouths), and copperheads are the most numerous and cause the most snake bites in the United States. Elapids (coral snakes) and imported exotic snakes cause a smaller number [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estimates from the 1960s suggest that there were approximately 8000 bites annually from poisonous snake species in the United States, with 10 to 12 deaths annually [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/2\">",
"     2",
"    </a>",
"    ]. Additional studies of rattlesnake bites suggest that there is an increasing number of significant bites, but mortality has remained at low levels since the 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 5000 snake bites are reported to the American Association of Poison Control Centers annually [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/4\">",
"     4",
"    </a>",
"    ]. Most of these occur in adult males. Hospitalization occurs in about half of all envenomated patients. Clinical effects are more severe in children and in victims of rattlesnake or water moccasin (cottonmouth) envenomation. Most snake bites occur in the summer months when snakes are most active. Southern and western states with warmer climates report the greatest number of venomous snake bites, including Texas, Florida, California, Arizona, Louisiana, Georgia, and North Carolina.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GEOGRAPHICAL DISTRIBUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rattlesnakes, water moccasins (cottonmouths), and copperheads are widely distributed throughout the United States:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rattlesnake (Crotalus and Sistrurus species) &ndash; Rattlesnakes live throughout the continental United States; they are native to all states except Alaska, Hawaii, and Maine.",
"     </li>",
"     <li>",
"      Water moccasin or cottonmouth (Agkistrodon piscivorus) &ndash; These snakes are found in the Southeast and South, from Virginia to Texas.",
"     </li>",
"     <li>",
"      Copperhead (Agkistrodon contortrix) &ndash; These snakes are common in the Eastern-half of the continental United States, from Massachusetts to Texas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of the effects of snake venom and US distribution of snakes is important when assessing and treating patients. Symptomatic Crotalinae (rattlesnake, water moccasin, or copperhead) envenomations are best considered as envenomation syndromes, typically [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Local tissue damage &ndash; Ecchymosis and progressive tissue swelling (",
"      <a class=\"graphic graphic_picture graphicRef73921 \" href=\"UTD.htm?18/19/18736\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Non-specific systemic effects &ndash; Nausea, vomiting, diarrhea, weakness, light-headedness, diaphoresis, or chills",
"     </li>",
"     <li>",
"      Coagulopathy &ndash; Bleeding",
"     </li>",
"     <li>",
"      Rhabdomyolysis with nephrotoxicity",
"     </li>",
"     <li>",
"      Increased vascular permeability, tachycardia, tachypnea, and hypotension",
"     </li>",
"     <li>",
"      Neurotoxicity (eg, oral paresthesia, unusual taste, fasciculations, altered mental status, seizures)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Crotalid bites usually do not cause neuromuscular weakness with respiratory depression except in victims of Mojave rattlesnake (Crotalus scutulatus).",
"   </p>",
"   <p>",
"    In general, rattlesnake envenomations cause more severe signs and symptoms than water moccasins (cottonmouths), and copperheads usually cause only limited local tissue swelling and pain with no systemic symptoms. However, the identity of the offending snake is often unknown. In addition, bites from any of the Crotalid snakes (rattlesnake, water moccasin [cottonmouth], or copperhead) may cause clinically significant findings. Thus, treatment of any suspected Crotalid bite should proceed based on signs and symptoms (",
"    <a class=\"graphic graphic_table graphicRef53948 \" href=\"UTD.htm?2/31/2556\">",
"     table 1",
"    </a>",
"    ) irrespective of the snake species, unless a snake expert has made a definite identification. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Supportive care'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H17\">",
"     'Crotalinae (Pit viper) antivenom'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     FIRST AID APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appropriate management of snake bites is controversial, and management strategies are primarily based on case series and clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/6\">",
"     6",
"    </a>",
"    ]. Numerous field measures have been advocated, but none have been shown to improve outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The authors suggest the following measures for US Crotalinae snake bite victims prior to definitive hospital care [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remove the patient from the snake's territory, and keep him or her warm, at rest, and calm.",
"     </li>",
"     <li>",
"      Immobilize the injured body part in a functional position at the level of the heart initially [",
"      <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/6\">",
"       6",
"      </a>",
"      ]. Further actions should be guided by an experienced clinician. Decisions regarding dependency or elevation of the bitten part must balance a potential increase in local injury with that for increased systemic venom absorption. Placing the extremity below the level of the heart may lead to increased tissue damage in some patients but may be appropriate in patients who have systemic effects of envenomation [",
"      <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/1\">",
"       1",
"      </a>",
"      ]. In contrast, elevation of a swollen extremity to prevent acute swelling in patients without systemic symptoms may subsequently increase systemic venom absorption but may be acceptable if the time to definitive care, including antivenom administration, is short [",
"      <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Remove any rings, watches, or constrictive clothing from the affected extremity.",
"     </li>",
"     <li>",
"      Do",
"      <strong>",
"       not",
"      </strong>",
"      apply pressure immobilization, tourniquets, or constrictive dressings. (See",
"      <a class=\"local\" href=\"#H21171190\">",
"       'Pressure immobilization'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Cleanse the wound.",
"     </li>",
"     <li>",
"      Withhold alcohol and drugs that may confound clinical assessment.",
"     </li>",
"     <li>",
"      Avoid potentially harmful therapies. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Techniques to avoid'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Transport the patient in the supine position to the nearest medical facility as quickly as possible, preferably using emergency medical services.",
"     </li>",
"     <li>",
"      Attempts to identify the snake should not endanger the patient or rescuer and should never delay transport to a medical facility. A digital photo taken at a safe distance may be useful. Snake parts should not be handled directly because the bite reflex may remain intact in recently killed snakes and result in additional envenomation [",
"      <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Venomous or nonvenomous?",
"    </span>",
"    &nbsp;&mdash;&nbsp;It may be difficult to determine whether a snake is venomous or not. Several characteristics have been proposed, but are not a substitute for expert consultation (",
"    <a class=\"graphic graphic_figure graphicRef73865 \" href=\"UTD.htm?31/51/32569\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/1\">",
"     1",
"    </a>",
"    ]. Venomous rattlesnakes have a triangular shaped head, elliptical pupils, and hollow, retractable fangs. In contrast, nonvenomous snakes have rounded head, round pupils, and lack fangs.",
"   </p>",
"   <p>",
"    Misidentification (particularly in an emergency situation) may have potentially serious outcomes, and patients with possible envenomation should be observed closely [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Techniques to avoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methods, such as tourniquets, incision and oral suction, mechanical suction devices, cryotherapy, surgery, and electric shock therapy, have been advocated in the past, but are no longer recommended (",
"    <a class=\"graphic graphic_algorithm graphicRef63835 \" href=\"UTD.htm?2/44/2757\">",
"     algorithm 1",
"    </a>",
"    ). Tourniquets can damage nerves, tendons, and blood vessels, and oral suction can lead to infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/1,9,10\">",
"     1,9,10",
"    </a>",
"    ]. Furthermore, venom removal by mechanical suction is minimal. In a study of mock venom extraction with a mechanical suction device in human volunteers, suction reduced the total body venom burden by only 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The suggested first aid approach for patients with suspected Crotalinae envenomation is discussed in detail separately. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'First aid approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21171190\">",
"    <span class=\"h3\">",
"     Pressure immobilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that patients with Crotalinae envenomation",
"    <strong>",
"     not",
"    </strong>",
"    receive pressure immobilization. Pressure immobilization refers to a procedure in which an elastic bandage is applied to the affected limb with a goal of achieving a bandage pressure of 55 to 70 mmHg. This method may delay systemic absorption of snake venom by preventing lymphatic spread in the affected limb. Although pressure immobilization is mentioned as a potential first aid therapy for snake bites in the United States by the American Heart Association [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/12\">",
"     12",
"    </a>",
"    ], no studies have demonstrated benefit in humans envenomated by Crotalinae species. Most snake bite experts do not support pressure immobilization for Crotalinae snake bites because these venoms cause local tissue toxicity and sequestering the venom in the affected limb may increase local tissue damage [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pressure immobilization may be useful as a first aid procedure for neurotoxic snake bite and is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31431?source=see_link&amp;anchor=H4#H4\">",
"     \"Principles of snake bite management worldwide\", section on 'Pressure immobilization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A unified treatment algorithm for Crotalinae snake bite management in the United States has been developed based upon literature review and expert opinion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/13\">",
"     13",
"    </a>",
"    ]. Based upon this approach, clinical assessment and ancillary studies are indicated to determine the degree of toxicity and to guide the use of antivenom (",
"    <a class=\"graphic graphic_table graphicRef53948 \" href=\"UTD.htm?2/31/2556\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef72265 \" href=\"UTD.htm?18/31/18935\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical evaluation begins with an assessment of the wound site and local adjacent tissues. \"Dry bites\" (in which no venom was injected) occur in approximately 25 percent of Crotalinae snake bites in the United States and show only minimal local irritation. True envenomation produces swelling, pain, ecchymoses, and blistering. Proximal spread of these signs suggests progressive toxicity.",
"   </p>",
"   <p>",
"    Systemic reactions, such as nausea, vomiting, abdominal pain, paresthesias, and dizziness, suggest more severe envenomation. Hypotension and altered mental status are ominous findings.",
"   </p>",
"   <p>",
"    Mojave rattlesnake envenomation does not typically produce significant local tissue reaction. With Mojave rattlesnake bites, serial neurologic examinations should be performed for at least 12 hours since onset of neurologic findings may be delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation for suspected Crotalinae envenomation (rattlesnake, water moccasin, or copperhead bite) should include the following studies to assess for evidence of coagulopathy and rhabdomyolysis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Serum electrolytes and creatinine and blood urea nitrogen",
"     </li>",
"     <li>",
"      Serum creatine kinase (CK)",
"     </li>",
"     <li>",
"      Prothrombin time (PT) and partial thromboplastin time (PTT)",
"     </li>",
"     <li>",
"      International normalized ratio (INR)",
"     </li>",
"     <li>",
"      Fibrin degradation products (fibrin split products [FSP])",
"     </li>",
"     <li>",
"      Fibrinogen",
"     </li>",
"     <li>",
"      D-dimer",
"     </li>",
"     <li>",
"      Urinalysis",
"     </li>",
"     <li>",
"      Electrocardiogram",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These studies should be repeated at regular intervals. The frequency of repeated measurements varies depending on the patient's clinical status (",
"    <a class=\"graphic graphic_algorithm graphicRef72265 \" href=\"UTD.htm?18/31/18935\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Wound management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetanus prophylaxis should be administered to snake bite patients according to the recommended immunization schedule (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although snake bites may result in the inoculation of bacteria, infection is rare. In a prospective observational study of 53 patients, there were no cases of documented infection following snake bite [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/17\">",
"     17",
"    </a>",
"    ]. Antibiotics (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    ) should only be administered for established infections [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/1\">",
"     1",
"    </a>",
"    ] or for heavily contaminated wounds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antivenom administration is the mainstay for treatment of significant Crotalinae (rattlesnake, water moccasin, copperhead) envenomation in the US. The indications and use of antivenom are discussed below. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Crotalinae (Pit viper) antivenom'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, the clinician should monitor for and be ready to manage coagulopathy, rhabdomyolysis, and compartment syndrome following Crotalinae envenomation and respiratory failure following Mojave rattlesnake bite.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Coagulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The coagulopathy associated with Crotalinae (rattlesnake, water moccasin, or copperhead) envenomation is due to thrombin-like glycoproteins within the venom as well as thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/5\">",
"     5",
"    </a>",
"    ]. This is in contrast to true disseminated intravascular coagulation (DIC) where fibrinolysis is activated by increased levels of endogenous thrombin. Thus, antivenom administration, and not coagulation factor replacement, is the primary treatment for Crotalinae-induced coagulopathy. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Crotalinae (Pit viper) antivenom'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Transfused platelets and coagulation factors in fresh frozen plasma are inactivated by Crotalinae venom and should be avoided in patients with Crotalinae-induced coagulopathy unless the patient has significant bleeding that is uncontrolled by high dose antivenom administration (",
"    <a class=\"graphic graphic_algorithm graphicRef63835 \" href=\"UTD.htm?2/44/2757\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because Crotalinae-induced coagulopathy arises from thrombin-like substances in the venom that are not inhibited by antithrombin III,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is also ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/5,18\">",
"     5,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Rhabdomyolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue destruction caused by snake envenomation may lead to muscle cell breakdown (rhabdomyolysis) with significant risk for renal failure. Patients with rhabdomyolysis typically present with the triad of pigmented granular casts in the urine, a red to brown color of the urine supernatant, and a marked elevation in the plasma level of creatine kinase (CK). Primary treatment goals consist of fluid repletion and evaluation for significant electrolyte abnormalities (hyperkalemia, hyperphosphatemia, hypocalcemia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link&amp;anchor=H11512176#H11512176\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15934647\">",
"    <span class=\"h3\">",
"     Elevated tissue pressures and compartment syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated tissue or compartment pressures may complicate Crotalinae (rattlesnake, water moccasin, or copperhead) bites. Any dressing, constriction band, splint, cast, or other restrictive covering should be removed. Venom is usually introduced into the subcutaneous tissues, and most, if not all, edema&nbsp;occurs in&nbsp;this space. Tissue pressures may increase because of the massive amounts of subcutaneous tissue fluid and because the skin has limits to its elasticity. Swelling, pain, and paresthesias may occur in patients after Crotalinae snake bite even in the absence of elevated tissue or compartment pressures. Thus, surgical intervention based on clinical findings alone is inappropriate (",
"    <a class=\"graphic graphic_algorithm graphicRef63835 \" href=\"UTD.htm?2/44/2757\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Generally,&nbsp;increased compartment pressures result from this extrinsic&nbsp;pressure and&nbsp;can be reduced with the administration of adequate amounts of antivenom and elevation. Elevation is usually avoided in true compartment syndromes and prior to antivenom administration in patients with venomous snake bites. After antivenom administration, however, elevation results in the drainage of subcutaneous edema and&nbsp;contributes to the reduction of the source of increased tissue pressure. If there is a concern for clinically significant,&nbsp;increased tissue, or compartment pressures, direct measurement with an appropriate device should be performed to guide additional management with antivenom and elevation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link&amp;anchor=H10#H10\">",
"     \"Acute compartment syndrome of the extremities\", section on 'Measurement of compartment pressures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ensuring adequate antivenom treatment is essential. In one case report and one case series, the only patients who received fasciotomy appeared to have inadequate dosing or duration of antivenom therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The role&nbsp;of dermatomy in the hand, when pressures&nbsp;are high enough to impair distal blood flow despite adequate antivenom and&nbsp;elevation, has never been demonstrated, and it is likely that providing an increased capacity for swelling&nbsp;will only result in additional fluid&nbsp;accumulation, with no ultimate benefit. By contrast, nonsurgical management of acute compartment syndrome in the hand has been described; a patient with a rattlesnake bite to the thenar eminence and a compartment pressure of 55 mmHg had full recovery after receiving large amounts of polyvalent Crotalinae antivenom (46 vials total) and 20 grams of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    True compartment syndromes may result from direct compartmental injection of venom, particularly with the anterior tibial compartment, which is very close to the skin. In these instances, antivenom and elevation may still reduce compartment pressures by the reduction of extrinsic pressure, but persistent intracompartmental pressures may remain high. The indications for fasciotomy in this context are unclear. An animal model of direct compartmental injection of venom demonstrated improved outcomes with antivenom alone versus antivenom plus fasciotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/22\">",
"     22",
"    </a>",
"    ]. However, in this model, fasciotomy was performed immediately after venom injection. Thus, surgical intervention for elevated compartment pressures following Crotalinae snake bite is controversial and should be guided by a medical toxicologist and surgeon with extensive experience caring for victims with snake bite.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CROTALINAE (PIT VIPER) ANTIVENOM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyvalent Crotalinae ovine immune Fab (FabAV, Crofab&reg;, Protherics) is the antivenom available in the United States for Crotalinae (rattlesnake, water moccasin, or copperhead) envenomation. An older antidote, Antivenin Crotalidae Polyvalent (ACP, Wyeth), was derived from horse serum and has not been distributed since 2002. All US stocks of ACP are expired as of March 2007.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Action",
"      </strong>",
"      &ndash; FabAV consists of the purified Fab fragments of sheep immunoglobulin (IgG) raised against the antivenom of four snakes: Crotalus atrox (Western diamondback rattlesnake), Crotalus adamanteus (Eastern diamondback rattlesnake), Crotalus scutulatus (Mojave rattlesnake), and Agkistrodon piscivorus (cottonmouth or water moccasin) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/23\">",
"       23",
"      </a>",
"      ]. When infused, these Fab fragments bind venom in the intravascular space and are renally excreted. The half-life of FabAV is shorter than Crotalinae venom substances. Thus, recurrent toxicity is possible despite initial control of local and systemic effects and may necessitate repeated FabAV administration. FabAV appears most effective when given within six hours of envenomation [",
"      <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consultation with a medical toxicologist is recommended prior to FabAV administration unless the physician has experience with snake bite treatment. Phone consultation with a medical toxicologist is available through a United States regional poison control center by calling 1-800-222-1222. Antivenom therapy is most effective when given within six hours of envenomation. Its use should be determined by the clinical severity of the bite and not the presumed species of snake responsible for the bite (",
"    <a class=\"graphic graphic_table graphicRef53948 \" href=\"UTD.htm?2/31/2556\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef72265 \" href=\"UTD.htm?18/31/18935\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend that patients with Crotalinae bites (rattlesnake, water moccasin [cottonmouth], or copperhead bites) and moderate to severe toxicity (",
"    <a class=\"graphic graphic_table graphicRef53948 \" href=\"UTD.htm?2/31/2556\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef72265 \" href=\"UTD.htm?18/31/18935\">",
"     algorithm 2",
"    </a>",
"    )&nbsp;",
"    <strong>",
"     or",
"    </strong>",
"    with bite sites that present a significant possibility for airway obstruction from local tissue swelling (eg, bites to the face or neck) receive FabAV therapy. In such patients, the benefit of treating life-threatening toxicity clearly outweighs the potential risk of hypersensitivity.",
"   </p>",
"   <p>",
"    We suggest that patients with Crotalinae envenomation but minimal and non-progressing swelling, pain, or ecchymosis not receive FabAV (",
"    <a class=\"graphic graphic_table graphicRef53948 \" href=\"UTD.htm?2/31/2556\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef72265 \" href=\"UTD.htm?18/31/18935\">",
"     algorithm 2",
"    </a>",
"    ).&nbsp;These patients warrant close assessment for 12 to 24 hours to ensure that progression of toxicity as indicated by worsening local or systemic effects do not occur. The duration of observation may vary with a number of factors, including the age and health of the patient, the social supports available on discharge, the presumed species of the snake and the location of the bite. Patients with confirmed copperhead bites appear to be at lower risk for systemic toxicity and progressive swelling. Based upon case series, these patients frequently fully recover without FabAV therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. However, expert guidance for FabAV use indicates that treatment decisions for copperhead envenomation should be based upon the same clinical criteria as rattlesnake or water moccasin (cottonmouth) bites [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to the availability of antivenoms active against Crotalinae snake bites and the widespread availability of emergency departments and critical care units, snake bite mortality ranged from 5 to 36 percent in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After the introduction of Antivenin Crotalidae Polyvalent (ACP, Wyeth) in the 1950s and the development of widespread availability of emergency and critical care medicine starting in the 1960s, deaths from snake bite dropped to less than 1 percent. For example, an observational study of 23,676 venomous snake exposures in the United States from 2001 to 2005 found a fatality rate of 0.06 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/4\">",
"     4",
"    </a>",
"    ]. Approximately half of these patients received either ACP or FabAV. Thus, the availability of antivenom for most native Crotalinae snake bites combined with secular trends in emergency and critical care capability has been associated with a marked decrease in snake bite mortality in the United States.",
"   </p>",
"   <p>",
"    Given this secular trend, most experts feel that performing randomized trials of antivenom administration in patients with severe envenomation is unethical. However, randomized trials in animals indicate that both antivenoms prevent death after injection of a variety of Crotalinae snake venoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/32-34\">",
"     32-34",
"    </a>",
"    ] and that FabAV provides even better protection than ACP [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/34\">",
"     34",
"    </a>",
"    ]. Although these clinical trials did not include patients&nbsp;exhibiting severe envenomation effects at the time of enrollment, some patients developed severe envenomation effects during their course, and subsequent observational evidence confirms that FabAV is effective for severe envenomation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3061369\">",
"     'Efficacy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Additional observational experience suggests that untreated Crotalinae envenomation is rarely fatal in regions where copperhead bites predominate, but is not infrequently life- or limb-threatening. For example, an observational study of 81 adult and pediatric patients who were managed without antivenom therapy after snake bite (45 copperhead, 12 water moccasin [cottonmouth], 10 rattlesnake, and 14 unknown) reported no fatalities or long-term morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/36\">",
"     36",
"    </a>",
"    ]. However, significant acute toxicity did occur, including coagulopathy (15 patients), skin necrosis (8 patients), respiratory distress requiring endotracheal intubation (3 patients), hypotension (2 patients), and cardiac arrhythmia (2 patients).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3061369\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for the use of FabAV in patients with Crotalinae bites are derived from one small open label trial in which FabAV was given to both treatment groups, observational studies, systematic reviews of individual cases, and post-marketing surveillance of adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/24,25,37-42\">",
"     24,25,37-42",
"    </a>",
"    ]. Studies suggest that FabAV controls the toxicity of Crotalinae bites in the majority of patients with minimal to moderate envenomation (",
"    <a class=\"graphic graphic_table graphicRef53948 \" href=\"UTD.htm?2/31/2556\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An open label multicenter trial of 31 patients 10 years of age or older, with minimal or moderate Crotalinae envenomation, who received FabAV within six hours of snake bite, demonstrated that FabAV controlled systemic toxicities in all 29 patients in whom they occurred and produced a significant reduction in the snake bite severity score [",
"      <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/37\">",
"       37",
"      </a>",
"      ]. An observational study of 24 children who received FabAV after a presumed Crotalinae snake bite found reduction of local tissue swelling in all patients [",
"      <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/41\">",
"       41",
"      </a>",
"      ]. Coagulopathy was reversed in 9 of 14 patients. One patient had acute hypersensitivity to FabAV.",
"     </li>",
"     <li>",
"      An observational study of 247 US snake bite victims presenting to 17 hospitals reported that 82 percent of patients achieved initial control of symptoms, defined as a lack of progressive local and systemic effects, no evident bleeding and improvement in platelet, and coagulation studies [",
"      <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/42\">",
"       42",
"      </a>",
"      ]. In those achieving initial control, the median initial number of vials administered was six, although the median number of vials administered during hospitalization was 10. Thrombocytopenia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neurologic effects on presentation were associated with the inability to achieve initial control.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Benefit from FabAV has also been described in patients with severe envenomation (",
"    <a class=\"graphic graphic_table graphicRef53948 \" href=\"UTD.htm?2/31/2556\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review of 24 individual cases of severe Crotalinae envenomation taken from cohort studies and case reports found that 50 of 65 severe venom effects improved or resolved after FabAV administration and that control of all signs and symptoms of envenomation occurred in 12 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/39\">",
"       39",
"      </a>",
"      ]. Recurrent or delayed coagulopathy was described in 12 patients.",
"     </li>",
"     <li>",
"      An observational study of 209 patients with Crotalinae snake bites reported outcomes after FabAV treatment in 28 patients with severe envenomation [",
"      <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/35\">",
"       35",
"      </a>",
"      ]. All patients with severe envenomation had clinical improvement after FabAV administration. Initial control of venom effects was achieved in 16 of 28 (57 percent) severely envenomated patients compared with 158 of 181 (87 percent) minimally or moderately envenomated patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these studies show that FabAV administration in patients with Crotalinae bites typically results in initial control of local and nonhematologic systemic toxicity. FabAV also halts progression of coagulopathy in most patients and prevents its occurrence. However, Crotalinae-induced coagulopathy or neurologic effects may be relatively resistant to antivenom therapy. FabAV dosing varies with disease severity and is described below. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Initial regimen based upon severity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Observational studies have identified hypersensitivity reactions as the main risk associated with FabAV therapy. In 2012, a meta-analysis estimated the incidence of immediate and delayed hypersensitivity following FabAV administration as 6 percent (95% CI: 4 to 9 percent, 463 patients) and 8 percent (95% CI: 4 to 16 percent, 298 patients), respectively, when studies confounded by product contamination were excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/43\">",
"     43",
"    </a>",
"    ]. These rates of hypersensitivity reactions are lower than those found in premarketing trials with a product containing a higher degree of Fc contamination [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/44,45\">",
"     44,45",
"    </a>",
"    ] and much lower than the rates of acute and delayed hypersensitivity previously seen after ACP administration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Known allergy to FabAV, papaya, or papain comprise absolute contraindications to FabAV administration in patients with minimal toxicity after a Crotalinae snake (rattlesnake, water moccasin [cottonmouth], or copperhead) bite (",
"    <a class=\"graphic graphic_table graphicRef53948 \" href=\"UTD.htm?2/31/2556\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians may choose to proceed with FabAV administration in patients who manifest serious systemic toxicity despite the presence of allergy. If this course of action is taken, then the patient should also receive pretreatment to blunt the allergic response (eg, IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    1.25",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum single dose 100 mg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    2",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum single dose 125 mg), and the clinician should ensure preparation and immediate availability of epinephrine (0.3 to 0.5 mg IM to the anterolateral thigh, 1:1000 preparation or continuous intravenous infusion of 1:10,000 epinephrine 0.1 to 1 microgram per minute, titrated to effect) before administration of any antivenom.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3061555\">",
"    <span class=\"h2\">",
"     Assessment of response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to FabAV determines whether or not further",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increasing doses are required. The adequacy of dosing should be evaluated based upon:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lack of progression of tissue swelling and ecchymosis adjacent to the bite site",
"     </li>",
"     <li>",
"      Improvement in vital signs, including decrease in tachycardia, tachypnea, and hypotension",
"     </li>",
"     <li>",
"      Improvement in other systemic findings including vomiting, diarrhea, pain, oral paresthesias, or altered mental status",
"     </li>",
"     <li>",
"      Partial or complete reversal of coagulopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Initial regimen based upon severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antivenom administration is associated with severe allergic reactions; it should only occur in a continuously monitored emergency or intensive care unit setting. Consultation with a medical toxicologist or other physician with expertise and prior experience treating venomous snake bites is strongly recommended before initiating antivenom therapy. Emergency consultation with a medical toxicologist in the United States is available at 1-800-222-1222. Outside of the United States, the World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    FabAV is supplied as a lyophilized powder that can be reconstituted in 10 mL within 20 minutes, but may take longer than 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/29\">",
"     29",
"    </a>",
"    ]. Each vial supplies approximately 1 g of total neutralizing proteins. The antivenom should be infused within four hours of preparation. The clinician should review the manufacturer's instructions prior to infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although studies have demonstrated low rates of acute reactions with FabAV [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/46\">",
"     46",
"    </a>",
"    ], we advocate the immediate",
"    <strong>",
"     availability",
"    </strong>",
"    of epinephrine (1:1000 [1",
"    <span class=\"nowrap\">",
"     mg/mL]",
"    </span>",
"    0.3 to 0.5 mg IM in the anterolateral thigh or 1:10,000 [0.1",
"    <span class=\"nowrap\">",
"     mg/mL]",
"    </span>",
"    prepared for continuous intravenous infusion),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    or similar antihistamine, intravenous corticosteroids, and inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    during antivenom administration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link&amp;anchor=H23#H23\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Pharmacologic treatments'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Snakes inject the same quantity of venom into children and adults. Thus, the dosage of antivenom is not dependent upon age or weight, but does vary with the",
"    <strong>",
"     severity of envenomation",
"    </strong>",
"    (",
"    <a class=\"graphic graphic_table graphicRef53948 \" href=\"UTD.htm?2/31/2556\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef72265 \" href=\"UTD.htm?18/31/18935\">",
"     algorithm 2",
"    </a>",
"    )",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with mild to moderate envenomation, FabAV is given in a dose of approximately 4 to 6 g (four to six vials) reconstituted and administered over 60 minutes, with repeat dosing of approximately 4 to 6 g (four to six vials) over 30 to 60 minutes if the patient has not responded after one hour [",
"      <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Higher doses are generally given to patients with severe envenomation (",
"      <a class=\"graphic graphic_algorithm graphicRef72265 \" href=\"UTD.htm?18/31/18935\">",
"       algorithm 2",
"      </a>",
"      ). In one study, initial control of severe venom effects occurred after a median of two doses of FabAV [",
"      <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/35\">",
"       35",
"      </a>",
"      ]. The doses consisted of a median of nine vials, with 25 percent of patients receiving more than 15 vials per dose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Treatment of acute hypersensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should immediately stop antivenom infusion in patients who experience signs of acute hypersensitivity (eg, anaphylactic shock, oropharyngeal swelling, bronchospasm, urticaria). These patients should receive treatment for anaphylaxis as outlined in the rapid overviews for anaphylaxis in adults (",
"    <a class=\"graphic graphic_table graphicRef58346 \" href=\"UTD.htm?16/26/16813\">",
"     table 3",
"    </a>",
"    ) and in children (",
"    <a class=\"graphic graphic_table graphicRef74242 \" href=\"UTD.htm?17/50/18221\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link&amp;anchor=H18#H18\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Immediate management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As acute reactions are often nonimmunologic in nature, the antivenom infusion may be resumed cautiously and completed at a lower infusion rate once initial signs of acute hypersensitivity have been treated.",
"   </p>",
"   <p>",
"    Allergic reactions can be secondary to venom sensitivity, particularly in those who have been bitten before or who handle snakes. In all cases of anaphylaxis, cessation of antivenom administration is part of the management of anaphylaxis. Once anaphylaxis is controlled, a decision regarding restarting the antivenom infusion should be based on a risk-to-benefit analysis, and antivenom should be administered at a lower infusion rate. Consultation with a medical toxicologist experienced in the management of Crotalinae snake bites is strongly recommended for these patients. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Treatment of recurrent toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients who receive antivenom warrant close observation for recurrent toxicity over the first 24 hours after initial FabAV administration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/37\">",
"     37",
"    </a>",
"    ]. Recurrent toxicity may occur despite initial control with antivenom. Recurrent symptoms may be local (eg, swelling), or systemic (eg, deterioration in the coagulation parameters following initial normalization). Recurrence may be related to the short half-life of Fab fragments or possibly dissociation of Fab fragment-venom complexes. In addition, antivenom may not reverse the thrombocytopenia following timber rattlesnake envenomation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that patients with Crotalinae bites and moderate-severe envenomation who have undergone FabAV administration receive scheduled doses of 2 g (two vials) every six hours for three doses to prevent recurrent toxicity (",
"    <a class=\"graphic graphic_table graphicRef53948 \" href=\"UTD.htm?2/31/2556\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef72265 \" href=\"UTD.htm?18/31/18935\">",
"     algorithm 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef63835 \" href=\"UTD.htm?2/44/2757\">",
"     algorithm 1",
"    </a>",
"    ). Alternatively, the clinician may chose to perform careful clinical assessment of the bite site and measurement of coagulation studies every six hours to determine the need for additional antivenom. Scheduled doses of FabAV appear to prevent recurrent toxicity. In an open label, multicenter trial of 31 patients who received an initial dose of FabAV with control of toxicity, the 15 patients who received scheduled treatment of approximately 2 g (two vials) every six hours for three doses did not experience recurrence while 8 of 16 patients in the group who only received further antivenom if recurrent symptoms developed required no further antivenom therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some instances, total reversal of coagulopathy with FabAV is not possible, and the clinician may choose improvement in coagulation parameters towards normal as an acceptable outcome in patients who have no significant bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Risk of late coagulopathy",
"      </strong>",
"      &ndash; Patients with abnormal coagulation within the first 12 hours after FabAV administration have a 67 percent chance of developing recurrent coagulopathy and should have repeat coagulation profiles checked every 48 hours until normal [",
"      <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/48\">",
"       48",
"      </a>",
"      ]. The mechanism of late recurrent coagulopathy is not known, but various mechanisms involving dissociation of venom-antivenom complexes have been suggested.",
"      <br/>",
"      <br/>",
"      Additional markers for late, persistent, or recurrent coagulopathy in patients who have received FabAV include abnormalities within 48 hours of a snake bite in platelet count, PT, PTT, INR, D-dimer, fibrinogen, or fibrin split products or a rise of &ge;20 percent in platelet count within four hours of FabAV administration regardless of initial platelet count [",
"      <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/49\">",
"       49",
"      </a>",
"      ]. Patients who have normal coagulation testing and &lt;20 percent increase in platelet count within four hours of FabAV administration may be at lower risk. However, all patients who receive FabAV should have reassessment of their coagulation status within five days after antivenom administration.",
"      <br/>",
"      <br/>",
"      Redosing of FabAV after the initial phase of treatment and maintenance antivenom therapy, is warranted even up to several weeks after envenomation. For patients who have bleeding or any of the following findings suggestive of ongoing venom effects on reassessment of coagulation [",
"      <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/48\">",
"       48",
"      </a>",
"      ]. An initial bolus dose of 2 g (two vials) is a reasonable starting point, with additional doses titrated to the neutralization of ongoing venom effects. A continuous infusion of FabAV may be a more efficient way to maintain a continuously protective, circulating concentration of antivenom, but should only be performed in consultation with a medical toxicologist with expertise in managing Crotalinae snake bites.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Plasma fibrinogen &lt;50",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"     </li>",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &lt;25,000/mL",
"      </span>",
"     </li>",
"     <li>",
"      International normalized ratio (INR) &gt;3.0",
"     </li>",
"     <li>",
"      Activated PTT &gt;50 sec",
"     </li>",
"     <li>",
"      Multiple defects in coagulation parameters",
"     </li>",
"     <li>",
"      Comorbid conditions or behaviors that increase hemorrhagic risk",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If late recurrent, persistent or late, new onset hematologic abnormalities develop, they may persist for more than two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients who require treatment with antivenom require hospital admission for further observation and supportive care. Hospitalization is also warranted in the United States for exotic, non-US snake bites, even in the setting of initially normal clinical appearance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31431?source=see_link\">",
"     \"Principles of snake bite management worldwide\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with possible Crotalinae (rattlesnake, water moccasin [cottonmouth], copperhead) envenomation who initially have mild or no toxicity on clinical assessment and normal baseline testing, may be observed for features of local and systemic toxicity. If the patient appears well and repeat laboratory tests remain normal at 8 to 12 hours, it is likely that no significant envenomation has occurred, and the patient may be discharged. A longer period of observation up to 24 hours may be necessary for children and the elderly, those with significant comorbidities, those with poor social supports, patients with some symptoms of envenomation and bites involving the lower limb or",
"    <span class=\"nowrap\">",
"     face/neck.",
"    </span>",
"   </p>",
"   <p>",
"    A somewhat longer period of observation (12 to 24 hours) is necessary for asymptomatic patients with suspected Mojave rattlesnake bites, since neurotoxicity may be delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21171547\">",
"    <span class=\"h2\">",
"     Discharge instructions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who do not receive antivenom should be instructed to seek medical care for increased swelling not relieved by elevation, signs of coagulopathy (easy bruising, petechiae, bleeding from gums or hematochezia), or pain not controlled by oral analgesia (",
"    <a class=\"graphic graphic_algorithm graphicRef63835 \" href=\"UTD.htm?2/44/2757\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients who have received antivenom should also receive the following instructions (",
"    <a class=\"graphic graphic_algorithm graphicRef63835 \" href=\"UTD.htm?2/44/2757\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seek care if they develop symptoms of serum sickness (fever, rash, muscle pain, arthralgia, or arthritis). &nbsp;",
"     </li>",
"     <li>",
"      If they had coagulopathy during their care or were victims of a rattlesnake envenomation, they should avoid contact sports, surgery, or dental work for two weeks.",
"     </li>",
"     <li>",
"      Patients bitten by a rattlesnake or water moccasin (cottonmouth) should also have prothrombin time, fibrinogen, hemoglobin, and platelets measured two to three days and five to seven days after the bite.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most victims of venomous North American snakes fully recover. Morbidity is uncommon and associated with bites to the face or upper extremity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/5\">",
"     5",
"    </a>",
"    ]. Loss of range of motion is most common. Other permanent sequelae include weakness, pain, abnormal sensation (paresthesia, hypesthesia, anesthesia), or skin discoloration.",
"   </p>",
"   <p>",
"    Death following Crotalinae snake bite is unusual (&lt;1 percent of all bites). Mortality is associated with rattlesnake bites, proximal bite sites (eg, face, neck, trunk), no antivenom therapy or inadequate antivenom dosing, or inadequate fluid resuscitation of shock [",
"    <a class=\"abstract\" href=\"UTD.htm?5/52/5962/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phone number for the National Poisons Information hotline, administered by the American Association of Poison Control Centers, is 1-800-222-1222. For clinicians outside of the United States, the World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most bites in the United States are caused by rattlesnakes, water moccasins (or cottonmouths), and copperheads (family Viperidae, subfamily Crotalinae). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic Crotalinae (rattlesnake, water moccasin, or copperhead) envenomation typically causes local tissue damage with ecchymosis (",
"      <a class=\"graphic graphic_picture graphicRef73921 \" href=\"UTD.htm?18/19/18736\">",
"       picture 1",
"      </a>",
"      ) and coagulopathy. Other potential sequelae include marked tissue swelling with compartment syndrome, rhabdomyolysis with renal failure, shock, hemorrhage, coma, and seizures. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical Manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      First aid measures for patients with Crotalinae (rattlesnake, water moccasin [cottonmouth], or copperhead) bites consist of removal from the vicinity of the snake, keeping the patient calm and at rest, immobilizing the affected extremity above the level of the heart, and rapid transport to definitive care. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'First aid approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with Crotalinae bites (rattlesnake, water moccasin [cottonmouth], or copperhead bites)",
"      <strong>",
"       not",
"      </strong>",
"      receive pressure immobilization (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21171190\">",
"       'Pressure immobilization'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Evaluation and management of Crotalinae (rattlesnake, water moccasin, or copperhead) envenomation is outlined in the algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef72265 \" href=\"UTD.htm?18/31/18935\">",
"       algorithm 2",
"      </a>",
"      ). The severity of the bite (",
"      <a class=\"graphic graphic_table graphicRef53948 \" href=\"UTD.htm?2/31/2556\">",
"       table 1",
"      </a>",
"      ) determines the need to give polyvalent Crotalinae ovine immune Fab (FabAV, Crofab&reg;, Protherics). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Crotalinae (Pit viper) antivenom'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Consultation with a medical toxicologist or other physician with experience in managing North American snake bites is strongly recommended prior to antivenom administration. Phone consultation with a medical toxicologist is available through a United States regional poison control center by calling 1-800-222-1222.",
"     </li>",
"     <li>",
"      We recommend that patients with Crotalinae bites (rattlesnake, water moccasin [cottonmouth], or copperhead bites) and moderate to severe toxicity (",
"      <a class=\"graphic graphic_table graphicRef53948 \" href=\"UTD.htm?2/31/2556\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef72265 \" href=\"UTD.htm?18/31/18935\">",
"       algorithm 2",
"      </a>",
"      )&nbsp;",
"      <strong>",
"       or",
"      </strong>",
"      with bite sites that present a significant possibility for airway obstruction from local tissue swelling (eg, bites to the face or neck) receive FabAV therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Initial regimen based upon severity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with Crotalinae bites with moderate to severe envenomation who have received FabAV be given additional scheduled doses of FabAV to prevent recurrent toxicity (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Treatment of recurrent toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with Crotalinae bites (rattlesnake, water moccasin [cottonmouth], or copperhead bites) and minimal toxicity (",
"      <a class=\"graphic graphic_table graphicRef53948 \" href=\"UTD.htm?2/31/2556\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef72265 \" href=\"UTD.htm?18/31/18935\">",
"       algorithm 2",
"      </a>",
"      )&nbsp;",
"      <strong>",
"       not",
"      </strong>",
"      receive FabAV therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These patients warrant close observation over 12 to 24 hours to ensure that progression of toxicity, as indicated by worsening local or systemic effects, does not occur. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinician should immediately stop antivenom infusion in patients who experience signs of acute hypersensitivity (eg, anaphylactic shock, oropharyngeal swelling, bronchospasm, urticaria). These patients should receive treatment for anaphylaxis as outlined in the rapid overviews for anaphylaxis in adults (",
"      <a class=\"graphic graphic_table graphicRef58346 \" href=\"UTD.htm?16/26/16813\">",
"       table 3",
"      </a>",
"      ) and in children (",
"      <a class=\"graphic graphic_table graphicRef74242 \" href=\"UTD.htm?17/50/18221\">",
"       table 4",
"      </a>",
"      ). Cautious resumption of antivenom administration may be appropriate in patients in whom the benefit of antivenom outweighs the risk of continued exposure. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Treatment of acute hypersensitivity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/1\">",
"      Gold BS, Dart RC, Barish RA. Bites of venomous snakes. N Engl J Med 2002; 347:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/2\">",
"      Parrish HM. Incidence of treated snakebites in the United States. Public Health Rep 1966; 81:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/3\">",
"      Walter FG, Stolz U, Shirazi F, McNally J. Epidemiology of severe and fatal rattlesnake bites published in the American Association of Poison Control Centers' Annual Reports. Clin Toxicol (Phila) 2009; 47:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/4\">",
"      Seifert SA, Boyer LV, Benson BE, Rogers JJ. AAPCC database characterization of native U.S. venomous snake exposures, 2001-2005. Clin Toxicol (Phila) 2009; 47:327.",
"     </a>",
"    </li>",
"    <li>",
"     Walter FG, Chase PB, Fernandez MC, McNally J. Venomous snakes. In: Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, 4th, Shannon MW, Borron SW, Burns MJ (Eds), Saunders, Philadelphia 2007. p.399.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/6\">",
"      Seifert S, White J, Currie BJ. Pressure bandaging for North American snake bite? No! Clin Toxicol (Phila) 2011; 49:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/7\">",
"      McKinney PE. Out-of-hospital and interhospital management of crotaline snakebite. Ann Emerg Med 2001; 37:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/8\">",
"      Corbett SW, Anderson B, Nelson B, et al. Most lay people can correctly identify indigenous venomous snakes. Am J Emerg Med 2005; 23:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/9\">",
"      Hall EL. Role of surgical intervention in the management of crotaline snake envenomation. Ann Emerg Med 2001; 37:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/10\">",
"      Stewart ME, Greenland S, Hoffman JR. First-aid treatment of poisonous snakebite: are currently recommended procedures justified? Ann Emerg Med 1981; 10:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/11\">",
"      Alberts MB, Shalit M, LoGalbo F. Suction for venomous snakebite: a study of \"mock venom\" extraction in a human model. Ann Emerg Med 2004; 43:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/12\">",
"      Markenson D, Ferguson JD, Chameides L, et al. Part 13: First aid: 2010 American Heart Association and American Red Cross International Consensus on First Aid Science With Treatment Recommendations. Circulation 2010; 122:S582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/13\">",
"      Lavonas EJ, Ruha AM, Banner W, et al. Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. BMC Emerg Med 2011; 11:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/14\">",
"      American College of Medical Toxicology, American Academy of Clinical Toxicology, American Association of Poison Control Centers, et al. Pressure immobilization after North American Crotalinae snake envenomation. J Med Toxicol 2011; 7:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/15\">",
"      American College of Medical Toxicology, American Academy of Clinical Toxicology, American Association of Poison Control Centers, et al. Pressure immobilization after North American Crotalinae snake envenomation. Clin Toxicol (Phila) 2011; 49:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/16\">",
"      RUSSELL FE, EVENTOV R. LETHALITY OF CRUDE AND LYOPHILIZED CROTALUS VENOM. Toxicon 1964; 15:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/17\">",
"      LoVecchio F, Klemens J, Welch S, Rodriguez R. Antibiotics after rattlesnake envenomation. J Emerg Med 2002; 23:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/18\">",
"      Tun Pe. Heparin therapy in Russell's viper bite victims with disseminated intravascular coagulation: a controlled trial. Southeast Asian J Trop Med Public Health 1992; 23:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/19\">",
"      Shaw BA, Hosalkar HS. Rattlesnake bites in children: antivenin treatment and surgical indications. J Bone Joint Surg Am 2002; 84-A:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/20\">",
"      Hardy DL Sr, Zamudio KR. Compartment syndrome, fasciotomy, and neuropathy after a rattlesnake envenomation: aspects of monitoring and diagnosis. Wilderness Environ Med 2006; 17:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/21\">",
"      Gold BS, Barish RA, Dart RC, et al. Resolution of compartment syndrome after rattlesnake envenomation utilizing non-invasive measures. J Emerg Med 2003; 24:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/22\">",
"      Tanen DA, Danish DC, Grice GA, et al. Fasciotomy worsens the amount of myonecrosis in a porcine model of crotaline envenomation. Ann Emerg Med 2004; 44:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/23\">",
"      Goto CS, Feng SY. Crotalidae polyvalent immune Fab for the treatment of pediatric crotaline envenomation. Pediatr Emerg Care 2009; 25:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/24\">",
"      Yip L. Rational use of crotalidae polyvalent immune Fab (ovine) in the management of crotaline bite. Ann Emerg Med 2002; 39:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/25\">",
"      Lavonas EJ, Gerardo CJ, O'Malley G, et al. Initial experience with Crotalidae polyvalent immune Fab (ovine) antivenom in the treatment of copperhead snakebite. Ann Emerg Med 2004; 43:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/26\">",
"      Whitley RE. Conservative treatment of copperhead snakebites without antivenin. J Trauma 1996; 41:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/27\">",
"      Caravati EM. Copperhead bites and Crotalidae polyvalent immune Fab (ovine): routine use requires evidence of improved outcomes. Ann Emerg Med 2004; 43:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/28\">",
"      Walker JP, Morrison RL. Current management of copperhead snakebite. J Am Coll Surg 2011; 212:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/29\">",
"      Dart RC, McNally J. Efficacy, safety, and use of snake antivenoms in the United States. Ann Emerg Med 2001; 37:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/30\">",
"      Hutchinson, RH. On the incidence of snakebite poisoning in the United States and the results of newer methods of treatment. Bull Antivenom Institute of America 1929; III:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/31\">",
"      do Amaral, A. The anti-snakebite campaign in Texas and in the subtropical United States. Bull Antivenom Institute of America 1927;I:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/32\">",
"      Dart RC, Goldner AP, Lindsey D. Efficacy of delayed administration of crotalid antivenom and crystalloid fluids. Toxicon 1988; 26:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/33\">",
"      Davidson TM. Intravenous rattlesnake envenomation. West J Med 1988; 148:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/34\">",
"      Consroe P, Egen NB, Russell FE, et al. Comparison of a new ovine antigen binding fragment (Fab) antivenin for United States Crotalidae with the commercial antivenin for protection against venom-induced lethality in mice. Am J Trop Med Hyg 1995; 53:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/35\">",
"      Lavonas EJ, Kokko J, Schaeffer TH, et al. Short-term outcomes after Fab antivenom therapy for severe crotaline snakebite. Ann Emerg Med 2011; 57:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/36\">",
"      Burch JM, Agarwal R, Mattox KL, et al. The treatment of crotalid envenomation without antivenin. J Trauma 1988; 28:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/37\">",
"      Dart RC, Seifert SA, Boyer LV, et al. A randomized multicenter trial of crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch Intern Med 2001; 161:2030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/38\">",
"      Johnson PN, McGoodwin L, Banner W Jr. Utilisation of Crotalidae polyvalent immune fab (ovine) for Viperidae envenomations in children. Emerg Med J 2008; 25:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/39\">",
"      Lavonas EJ, Schaeffer TH, Kokko J, et al. Crotaline Fab antivenom appears to be effective in cases of severe North American pit viper envenomation: an integrative review. BMC Emerg Med 2009; 9:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/40\">",
"      Ruha AM, Curry SC, Beuhler M, et al. Initial postmarketing experience with crotalidae polyvalent immune Fab for treatment of rattlesnake envenomation. Ann Emerg Med 2002; 39:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/41\">",
"      Pizon AF, Riley BD, LoVecchio F, Gill R. Safety and efficacy of Crotalidae Polyvalent Immune Fab in pediatric crotaline envenomations. Acad Emerg Med 2007; 14:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/42\">",
"      Yin S, Kokko J, Lavonas E, et al. Factors associated with difficulty achieving initial control with crotalidae polyvalent immune fab antivenom in snakebite patients. Acad Emerg Med 2011; 18:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/43\">",
"      Schaeffer TH, Khatri V, Reifler LM, Lavonas EJ. Incidence of immediate hypersensitivity reaction and serum sickness following administration of Crotalidae polyvalent immune Fab antivenom: a meta-analysis. Acad Emerg Med 2012; 19:121.",
"     </a>",
"    </li>",
"    <li>",
"     Protherics. CroFab: Crotalidae polyvalent immune Fab (ovine) product information. In: Nashville TN; 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/45\">",
"      Clark RF, McKinney PE, Chase PB, Walter FG. Immediate and delayed allergic reactions to Crotalidae polyvalent immune Fab (ovine) antivenom. Ann Emerg Med 2002; 39:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/46\">",
"      Cannon R, Ruha AM, Kashani J. Acute hypersensitivity reactions associated with administration of crotalidae polyvalent immune Fab antivenom. Ann Emerg Med 2008; 51:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/47\">",
"      Gold BS, Barish RA, Rudman MS. Refractory thrombocytopenia despite treatment for rattlesnake envenomation. N Engl J Med 2004; 350:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/48\">",
"      Boyer LV, Seifert SA, Cain JS. Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 2. Guidelines for clinical management with crotaline Fab antivenom. Ann Emerg Med 2001; 37:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/52/5962/abstract/49\">",
"      Seifert SA, I Kirschner R, Martin N. Recurrent, persistent, or late, new-onset hematologic abnormalities in Crotaline snakebite. Clin Toxicol (Phila) 2011; 49:324.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6595 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-99C72D4C66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_52_5962=[""].join("\n");
var outline_f5_52_5962=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H628739\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GEOGRAPHICAL DISTRIBUTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      FIRST AID APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Venomous or nonvenomous?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Techniques to avoid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21171190\">",
"      - Pressure immobilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INITIAL EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Wound management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Coagulopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15934647\">",
"      - Elevated tissue pressures and compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CROTALINAE (PIT VIPER) ANTIVENOM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3061369\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3061555\">",
"      Assessment of response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Initial regimen based upon severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Treatment of acute hypersensitivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Treatment of recurrent toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21171547\">",
"      Discharge instructions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6595\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6595|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?2/44/2757\" title=\"algorithm 1\">",
"      Crotalinae snakebite referral maintenance and follow up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?18/31/18935\" title=\"algorithm 2\">",
"      ED and hospital Crotalinae snakebite management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6595|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/51/32569\" title=\"figure 1\">",
"      Venomous vs nonvenomous",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6595|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/19/18736\" title=\"picture 1\">",
"      Water moccasin bite",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6595|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/31/2556\" title=\"table 1\">",
"      Class snake bite US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 2\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/26/16813\" title=\"table 3\">",
"      Emergent management of anaphylaxis in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/50/18221\" title=\"table 4\">",
"      Rapid overview for pediatric anaphylaxis treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/48/775?source=related_link\">",
"      Management of Elapidae (coral snake) bites in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31431?source=related_link\">",
"      Principles of snake bite management worldwide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_52_5963="CO2 waveform diagnostics";
var content_f5_52_5963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Waveform diagnostics",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Waveform",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chest wall movement",
"       </td>",
"       <td class=\"subtitle1\">",
"        Breath sounds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central apnea",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upper airway obstruction",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laryngospasm",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     +: Present.",
"     <br>",
"      -: Absent.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_52_5963=[""].join("\n");
var outline_f5_52_5963=null;
var title_f5_52_5964="Est dx MCTD";
var content_f5_52_5964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F74610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F74610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Two algorithms for establishing a diagnosis of mixed connective tissue disease (MCTD)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Alarcon-Segovia's criteria",
"       </td>",
"       <td class=\"subtitle1\">",
"        Kahn's criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        A. Serological criteria",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        A. Serological criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anti-RNP antibodies with a hemagglutination titer of &ge;1:1600",
"       </td>",
"       <td class=\"indent1\">",
"        High titer anti-RNP corresponding to a speckled ANA of &ge;1:1200 titer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        B. Clinical criteria",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        B. Clinical criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Swollen hands",
"       </td>",
"       <td class=\"indent1\">",
"        1. Swollen fingers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Synovitis",
"       </td>",
"       <td class=\"indent1\">",
"        2. Synovitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. Myositis*",
"       </td>",
"       <td class=\"indent1\">",
"        3. Myositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4. Raynaud's phenomenon",
"       </td>",
"       <td class=\"indent1\">",
"        4. Raynaud phenomenon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5. Acrosclerosis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        MCTD is present if:",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        MCTD is present if:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Criterion A is accompanied by 3 or more clinical criteria - one of which must include synovitis or myositis.",
"       </td>",
"       <td>",
"        Criterion A is accompanied by Raynaud phenomenon and 2 or more of the 3 remaining clinical criteria.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Myalgia is commonly substituted for myositis.",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Bennett RM. Overlap Syndromes. Kelley's Textbook of Rheumatology, 8th Edition, W.B. Saunders Co, Philadelphia 2009. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_52_5964=[""].join("\n");
var outline_f5_52_5964=null;
var title_f5_52_5965="Two day method algorithm";
var content_f5_52_5965=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Two day method algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 217px; height: 283px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Arevalo M, Jennings V, Nikula M, Sinai I. Efficacy of the new Two Day Method of family planning. Fertil Steril 2004; 82:885. Copyright &copy; 2004 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_52_5965=[""].join("\n");
var outline_f5_52_5965=null;
var title_f5_52_5966="Mild Hunter syndrome B";
var content_f5_52_5966=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mild mucopolysaccharidosis type II (MPS II, Hunter syndrome) B",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 123px; height: 367px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mild Hunter syndrome (MPS II) in a 12-year-old boy (lateral view).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ed Wraith, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_52_5966=[""].join("\n");
var outline_f5_52_5966=null;
var title_f5_52_5967="Stretch marks in Cushings PI";
var content_f5_52_5967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F59758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F59758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stretch marks caused by Cushing's syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 222px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows reddish-purple stretch marks on the belly and under the arms in a person with Cushing's syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David N Orth, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_52_5967=[""].join("\n");
var outline_f5_52_5967=null;
